This is a non-core endpoint: only basic statistics are computed.
Injury of blood vessels at lower leg level
ST19_INJURY_BLOOD_VESSE_LOWER_LEG_LEVEL
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519870 |
1. Apply sex-specific ruleNone |
519870 |
2. Check conditionsNone |
519870 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
173 |
4. Check minimum number of eventsNone |
173 |
5. Include endpointsNone |
173 |
6. Filter based on genotype QC (FinnGen only) |
167 |
Control definitions (FinnGen only)
- Control exclude
- ST19_INJURI_KNEE_LOWER_LEG
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF4
- Parent code in ICD-10
- S8
- Name in latin
- Laesio vasorum sanguineorum in regione genus/cruris
Similar endpoints
↥List of similar endpoints to
Injury of blood vessels at lower leg level
based on the number of shared cases.
Similar with more cases:
- Injuries to the knee and lower leg
- Injury, poisoning and certain other consequences of external causes
- Any operation in hilmo
- Any prescribed medicine buy
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 167 | 73 | 94 |
| Unadjusted period prevalence (%) | 0.04 | 0.03 | 0.04 |
| Median age at first event (years) | 53.81 | 50.77 | 56.17 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 173
- Matched controls
- 1730
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
S85.9
ICD-10 Finland
Injury of unspecified blood vessel at lower leg level
+∞
62.3
56
*
S83.5
ICD-10 Finland
Sprain and strain involving (anterior)(posterior) cruciate ligament of knee
561.3
45.4
43
*
X59
ICD-10 Finland
Exposure to unspecified factor
7.6
37.5
75
159
S85.0
ICD-10 Finland
Injury of popliteal artery
+∞
36.8
34
*
NGE35
NOMESCO Finland
Plastic repair of ligament of knee not using prosthetic material, anterior cruciate, arthroscopic
101.4
31.0
33
*
QDB10
NOMESCO Finland
Major dressing of wound of skin of lower limb
13.8
30.9
31
27
NGD05
NOMESCO Finland
Partial excision of meniscus of knee, arthroscopic
7.8
24.7
39
62
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
4.8
23.5
85
288
X58
ICD-10 Finland
Exposure to other specified factors
5.9
23.4
52
117
S85.1
ICD-10 Finland
Injury of (anterior)(posterior) tibial artery
+∞
22.4
21
*
S85.5
ICD-10 Finland
Injury of popliteal vein
+∞
22.4
21
*
S83.2
ICD-10 Finland
Tear of meniscus, current
36.7
22.3
28
9
NG1AA
NOMESCO Finland
Knee X-ray examination without contrast
6.4
21.8
42
82
QDB05
NOMESCO Finland
Revision of wound of skin of lower limb
22.9
20.3
29
15
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
5.8
20.0
43
93
S85.8
ICD-10 Finland
Injury of other blood vessels at lower leg level
+∞
19.1
18
*
NGM10
NOMESCO Finland
Fasciotomy of of knee or lower leg
+∞
19.1
18
*
ZZA00
NOMESCO Finland
Split skin graft
31.2
17.0
22
8
S81.8
ICD-10 Finland
Open wound of other parts of lower leg
21.5
14.6
21
11
S83.1
ICD-10 Finland
Dislocation of knee
+∞
13.7
13
*
NGJ70
NOMESCO Finland
External fixation of fracture of knee or lower leg, other or unspecified
+∞
13.7
13
*
ZXD05
NOMESCO Finland
Urgent procedure
3.4
13.1
71
297
S85.3
ICD-10 Finland
Injury of greater saphenous vein at lower leg level
+∞
12.7
12
*
S82.1
ICD-10 Finland
Fracture of upper end of tibia
139.7
12.6
13
*
NG4AA
NOMESCO Finland
Lower leg X-ray examination
20.8
11.8
17
9
N03AX16
ATC
[U] pregabalin
3.3
11.8
60
239
B01AB05
ATC
enoxaparin; parenteral
3.1
11.7
71
314
S83.6
ICD-10 Finland
Sprain and strain of other and unspecified parts of knee
16.6
11.6
18
12
S85.2
ICD-10 Finland
Injury of peroneal artery
+∞
11.6
11
*
NGU20
NOMESCO Finland
Removal of internal fixation device from knee or lower leg
116.8
10.5
11
*
Z3226
NOMESCO Finland
Physiotherapist
3.5
10.4
44
155
S83.0
ICD-10 Finland
Dislocation of patella
42.7
10.1
12
*
PEH57
NOMESCO Finland
Bypass from femoral artery to popliteal artery below knee
42.7
10.1
12
*
ZXE20
NOMESCO Finland
More than three and less than five hours
3.6
9.8
37
121
TNG34
NOMESCO Finland
Major custom moulded orthopaedic cast, knee or lower leg
38.9
9.1
11
*
S83.4
ICD-10 Finland
Sprain and strain involving (fibular)(tibial) collateral ligament of knee
11.6
9.0
16
15
NJ2MA
NOMESCO Finland
Measurement of mechanical axis of lower leg with X-ray
4.8
8.9
21
48
WX408
NOMESCO Finland
General anesthesy, balanced
2.8
8.6
57
259
QDE35
NOMESCO Finland
Repair of skin defect in lower limb after surgery or injury
+∞
8.4
8
*
S18
ICPC
Laceration/cut
2.6
8.4
98
586
TNX33
NOMESCO Finland
Custom moulded cast, unspecified region
10.8
8.2
15
15
S97
ICPC
Chronic ulcer skin
4.5
8.1
21
52
NG1BG
NOMESCO Finland
Knee and lower leg MRI examination with high intensity magnet
9.2
8.0
16
19
NGF25
NOMESCO Finland
Operation for osteochondritis of knee, arthroscopic
4.5
7.8
20
49
NH1AA
NOMESCO Finland
Ankle X-ray examination without contrast
7.7
7.7
17
24
Y83
ICD-10 Finland
Surgical operation and other surgical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
4.3
7.7
21
54
S83.7
ICD-10 Finland
Injury to multiple structures of knee
83.5
7.5
8
*
NHJ10
NOMESCO Finland
Internal fixation of fracture of ankle using wire, rod, cerclage or pin
83.5
7.5
8
*
TQW11
NOMESCO Finland
Vacuum treatment of wound
11.6
7.4
13
12
W22
ICD-10 Finland
Striking against or struck by other object(s)
4.7
7.4
18
42
PD4BD
NOMESCO Finland
Extensive CT of lower extremity arteries
+∞
7.3
7
*
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
3.1
7.3
35
132
ZXA00
NOMESCO Finland
Right side
2.6
7.3
54
257
S80.1
ICD-10 Finland
Contusion of other and unspecified parts of lower leg
9.9
6.9
13
14
R4110
NOMESCO Finland
Physiotherapy
2.5
6.8
57
286
S86.0
ICD-10 Finland
Injury of Achilles tendon
41.7
6.8
8
*
M17.3
ICD-10 Finland
Other post-traumatic gonarthrosis
12.9
6.7
11
9
T81.4
ICD-10 Finland
Infection following a procedure, not elsewhere classified
3.4
6.7
26
86
NGB20
NOMESCO Finland
Primary total prosthetic replacement of knee joint without patellar part
3.4
6.6
25
81
J01FF01
ATC
clindamycin; systemic
2.4
6.6
59
305
B01AA03
ATC
warfarin; systemic
2.7
6.5
39
166
NG1AD
NOMESCO Finland
Knee CT examination
15.1
6.5
10
7
W00
ICD-10 Finland
Fall on same level involving ice and snow
3.5
6.5
24
77
S89.9
ICD-10 Finland
Unspecified injury of lower leg
11.6
6.4
11
10
XPX99
NOMESCO Finland
Other diagnostic examination of periferal vessel
3.8
6.4
20
57
S81.0
ICD-10 Finland
Open wound of knee
18.9
6.3
9
5
NGU10
NOMESCO Finland
Removal of external fixation device from knee or lower leg
+∞
6.3
6
*
QD9S1
NOMESCO Finland
Photography of skin or subcutaneous tissue in lower extremities, unspecified
+∞
6.3
6
*
M79.6
ICD-10 Finland
Pain in limb
2.2
6.3
87
540
M17.0
ICD-10 Finland
Primary gonarthrosis, bilateral
2.9
6.2
33
131
L15
ICPC
Knee symptom/complaint
2.4
6.2
51
253
N02AX02
ATC
tramadol; systemic, rectal
2.2
6.2
85
525
Z76.9
ICD-10 Finland
Person encountering health services in unspecified circumstances
3.4
6.2
23
74
ZXD35
NOMESCO Finland
Usual procedure
7.7
6.0
13
18
JN3AD
NOMESCO Finland
Abdominal CT examination
2.9
6.0
32
127
TimeCodeWAS
↥TODO / Current known limitations:
- Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
- Legend / how to read the glyphs.
- Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
- Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
- Download CSV.
- No filters and sorters.
- Limited amount of endpoints (~400) having TimeCodeWAS data.
- Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Orthopedic Surgery
20 [38004465]
20 [38004465]
9.1e-01
1.7e+00
3.2e+00
—
3.0e+00
2.6e+00
1.4e+00
cases:20.93%
controls:9.65%
cases:19.19%
controls:4.24%
cases:9.88%
controls:0.47%
—
—
cases:15.79%
controls:0.93%
cases:38.92%
controls:4.42%
cases:38.62%
controls:13.21%
36
166
136
1554
33
73
139
1647
17
8
155
1712
—
27
16
144
1702
65
75
102
1620
56
201
89
1321
Outpatient Visit
OP [9202]
OP [9202]
3.0e-01
7.2e-01
1.1e+00
4.9e+00
1.5e+00
1.1e+00
9.9e-01
cases:66.86%
controls:59.83%
cases:56.98%
controls:39.19%
cases:18.60%
controls:6.80%
cases:27.33%
controls:0.29%
cases:26.32%
controls:7.68%
cases:67.66%
controls:41.12%
cases:84.83%
controls:67.61%
115
1029
57
691
98
674
74
1046
32
117
140
1603
47
5
125
1715
45
132
126
1586
113
697
54
998
123
1029
22
493
Outpatient Hospital
22 [8756]
22 [8756]
7.7e-01
1.2e+00
2.7e+00
—
2.5e+00
1.5e+00
1.0e+00
cases:36.63%
controls:21.05%
cases:18.60%
controls:6.45%
cases:7.56%
controls:0.52%
—
—
cases:9.94%
controls:0.93%
cases:21.56%
controls:5.72%
cases:36.55%
controls:16.82%
63
362
109
1358
32
111
140
1609
13
9
159
1711
—
17
16
154
1702
36
97
131
1598
53
256
92
1266
cefalexin; oral
J01DB01 [21602870]
J01DB01 [21602870]
9.3e-01
1.0e+00
2.4e+00
—
3.0e+00
1.2e+00
9.0e-01
cases:47.09%
controls:25.99%
cases:18.02%
controls:7.33%
cases:6.40%
controls:0.64%
—
—
cases:12.87%
controls:0.76%
cases:22.16%
controls:7.61%
cases:46.21%
controls:25.89%
81
447
91
1273
31
126
141
1594
11
11
161
1709
—
22
13
149
1705
37
129
130
1566
67
394
78
1128
Emergency Room Visit
ER [9203]
ER [9203]
6.9e-01
1.4e+00
2.5e+00
—
2.4e+00
1.2e+00
8.7e-01
cases:45.35%
controls:29.42%
cases:29.65%
controls:9.07%
cases:14.53%
controls:1.40%
—
—
cases:12.28%
controls:1.22%
cases:25.75%
controls:9.68%
cases:47.59%
controls:27.46%
78
506
94
1214
51
156
121
1564
25
24
147
1696
—
21
21
150
1697
43
164
124
1531
69
418
76
1104
Inpatient Hospital
21 [8717]
21 [8717]
6.6e-01
1.0e+00
2.2e+00
—
2.4e+00
1.4e+00
9.5e-01
cases:44.19%
controls:28.95%
cases:23.26%
controls:9.65%
cases:10.47%
controls:1.22%
—
—
cases:16.37%
controls:1.69%
cases:28.14%
controls:8.73%
cases:44.14%
controls:23.39%
76
498
96
1222
40
166
132
1554
18
21
154
1699
—
28
29
143
1689
47
148
120
1547
64
356
81
1166
General Surgery
2 [38004447]
2 [38004447]
8.4e-01
1.5e+00
—
1.0e+50
3.1e+00
2.2e+00
6.8e-01
cases:31.98%
controls:16.86%
cases:18.60%
controls:5.00%
—
—
cases:34.30%
controls:0.00%
cases:15.79%
controls:0.81%
cases:26.95%
controls:3.78%
cases:24.14%
controls:13.93%
55
290
117
1430
32
86
140
1634
—
59
0
113
1720
27
14
144
1704
45
64
122
1631
35
212
110
1310
Exposure to unspecified factor
X59 [45756412]
X59 [45756412]
1.4e+00
2.5e+00
1.0e+50
—
—
3.2e+00
1.8e+00
cases:5.23%
controls:1.34%
cases:6.98%
controls:0.58%
cases:3.49%
controls:0.00%
—
—
—
—
cases:13.17%
controls:0.59%
cases:11.03%
controls:2.10%
9
23
163
1697
12
10
160
1710
6
0
166
1720
—
—
22
10
145
1685
16
32
129
1490
General Practice
1 [38004446]
1 [38004446]
6.6e-01
1.1e+00
1.8e+00
—
2.2e+00
1.4e+00
7.6e-01
cases:18.02%
controls:10.23%
cases:12.21%
controls:4.48%
cases:4.65%
controls:0.81%
—
—
cases:9.36%
controls:1.11%
cases:15.57%
controls:4.42%
cases:22.76%
controls:12.09%
31
176
141
1544
21
77
151
1643
8
14
164
1706
—
16
19
155
1699
26
75
141
1620
33
184
112
1338
Fall on same level from slipping, tripping and stumbling
W01 [45756243]
W01 [45756243]
1.2e+00
2.5e+00
—
—
—
2.2e+00
1.3e+00
cases:8.14%
controls:2.56%
cases:9.30%
controls:0.87%
—
—
—
—
—
—
cases:11.98%
controls:1.47%
cases:11.03%
controls:3.35%
14
44
158
1676
16
15
156
1705
—
—
—
20
25
147
1670
16
51
129
1471
Treatment of chronic ulcer or burn
SPAT1148 [2001700249]
SPAT1148 [2001700249]
—
2.3e+00
—
—
—
2.8e+00
1.7e+00
—
—
cases:3.49%
controls:0.35%
—
—
—
—
—
—
cases:5.39%
controls:0.35%
cases:6.21%
controls:1.18%
—
6
6
166
1714
—
—
—
9
6
158
1689
9
18
136
1504
Physiotherapy
R4110 [2001310233]
R4110 [2001310233]
4.8e-01
1.3e+00
—
1.0e+50
3.2e+00
2.0e+00
8.9e-01
cases:6.40%
controls:4.07%
cases:6.40%
controls:1.74%
—
—
cases:9.30%
controls:0.00%
cases:7.02%
controls:0.29%
cases:11.38%
controls:1.77%
cases:9.66%
controls:4.20%
11
70
161
1650
11
30
161
1690
—
16
0
156
1720
12
5
159
1713
19
30
148
1665
14
64
131
1458
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
N02AX02 [21604298]
9.4e-01
1.2e+00
—
—
2.8e+00
1.5e+00
1.2e+00
cases:15.70%
controls:6.80%
cases:6.40%
controls:1.92%
—
—
—
—
cases:4.68%
controls:0.29%
cases:8.98%
controls:2.18%
cases:16.55%
controls:5.58%
27
117
145
1603
11
33
161
1687
—
—
8
5
163
1713
15
37
152
1658
24
85
121
1437
Vascular Surgery
77 [38004496]
77 [38004496]
5.0e-01
2.0e+00
—
—
—
2.6e+00
1.7e+00
cases:3.49%
controls:2.15%
cases:6.40%
controls:0.93%
—
—
—
—
—
—
cases:13.17%
controls:1.12%
cases:13.10%
controls:2.56%
6
37
166
1683
11
16
161
1704
—
—
—
22
19
145
1676
19
39
126
1483
Knee X-ray examination without contrast
NG1AA [2001308049]
NG1AA [2001308049]
1.6e+00
—
—
1.0e+50
—
3.3e+00
2.6e+00
cases:3.49%
controls:0.76%
—
—
—
—
cases:6.40%
controls:0.00%
—
—
cases:7.19%
controls:0.29%
cases:8.28%
controls:0.66%
6
13
166
1707
—
—
11
0
161
1720
—
12
5
155
1690
12
10
133
1512
oxycodone; oral, parenteral
N02AA05 [21604260]
N02AA05 [21604260]
—
2.2e+00
—
—
—
2.2e+00
1.3e+00
—
—
cases:3.49%
controls:0.41%
—
—
—
—
—
—
cases:5.99%
controls:0.71%
cases:7.59%
controls:2.17%
—
6
7
166
1713
—
—
—
10
12
157
1683
11
33
134
1489
codeine and paracetamol
N02AJ06 [1123647]
N02AJ06 [1123647]
5.6e-01
1.3e+00
1.4e+00
1.0e+50
2.1e+00
1.3e+00
8.8e-01
cases:16.86%
controls:10.41%
cases:12.21%
controls:3.72%
cases:4.07%
controls:1.05%
cases:3.49%
controls:0.00%
cases:6.43%
controls:0.81%
cases:11.38%
controls:3.24%
cases:26.21%
controls:12.81%
29
179
143
1541
21
64
151
1656
7
18
165
1702
6
0
166
1720
11
14
160
1704
19
55
148
1640
38
195
107
1327
pregabalin; oral
N02BF02 [955152]
N02BF02 [955152]
6.1e-01
1.3e+00
—
—
1.8e+00
1.9e+00
1.7e+00
cases:5.23%
controls:2.91%
cases:5.23%
controls:1.51%
—
—
—
—
cases:4.09%
controls:0.70%
cases:9.58%
controls:1.59%
cases:15.17%
controls:3.15%
9
50
163
1670
9
26
163
1694
—
—
7
12
164
1706
16
27
151
1668
22
48
123
1474
Infection following a procedure, not elsewhere classified
T81.4 [45575538]
T81.4 [45575538]
—
—
—
—
—
2.5e+00
2.5e+00
—
—
—
—
—
—
—
—
—
—
cases:4.19%
controls:0.35%
cases:6.21%
controls:0.53%
—
—
—
—
—
7
6
160
1689
9
8
136
1514
furosemide; oral, parenteral
C03CA01 [21601518]
C03CA01 [21601518]
1.3e+00
1.1e+00
1.1e+00
—
9.4e-01
1.2e+00
1.2e+00
cases:12.79%
controls:3.84%
cases:11.05%
controls:4.07%
cases:4.07%
controls:1.45%
—
—
cases:2.92%
controls:1.16%
cases:13.17%
controls:4.19%
cases:17.24%
controls:5.98%
22
66
150
1654
19
70
153
1650
7
25
165
1695
—
5
20
166
1698
22
71
145
1624
25
91
120
1431
warfarin; oral, parenteral
B01AA03 [21600965]
B01AA03 [21600965]
1.0e+00
1.3e+00
1.4e+00
—
1.4e+00
1.4e+00
1.1e+00
cases:11.63%
controls:4.42%
cases:11.63%
controls:3.60%
cases:2.91%
controls:0.76%
—
—
cases:3.51%
controls:0.93%
cases:12.57%
controls:3.54%
cases:11.72%
controls:4.14%
20
76
152
1644
20
62
152
1658
5
13
167
1707
—
6
16
165
1702
21
60
146
1635
17
63
128
1459
Emergency Room and Inpatient Visit
ERIP [262]
ERIP [262]
1.8e-01
1.8e+00
—
1.0e+50
2.9e+00
9.5e-01
4.4e-01
cases:2.91%
controls:2.44%
cases:5.81%
controls:1.05%
—
—
cases:8.14%
controls:0.00%
cases:5.26%
controls:0.29%
cases:6.59%
controls:2.65%
cases:8.97%
controls:5.98%
5
42
167
1678
10
18
162
1702
—
14
0
158
1720
9
5
162
1713
11
45
156
1650
13
91
132
1431
INR in Blood by Coagulation assay
34714-6 [3032080]
34714-6 [3032080]
3.1e-01
1.0e+00
1.8e+00
—
1.7e+00
1.2e+00
7.6e-01
cases:9.30%
controls:6.98%
cases:8.72%
controls:3.37%
cases:6.40%
controls:1.16%
—
—
cases:7.02%
controls:1.34%
cases:11.38%
controls:3.89%
cases:17.24%
controls:8.87%
16
120
156
1600
15
58
157
1662
11
20
161
1700
—
12
23
159
1695
19
66
148
1629
25
135
120
1387
Bacteria identified in Blood by Culture
600-7 [3023368]
600-7 [3023368]
7.4e-01
1.1e+00
—
—
2.2e+00
1.4e+00
1.0e+00
cases:5.81%
controls:2.85%
cases:5.23%
controls:1.74%
—
—
—
—
cases:4.68%
controls:0.52%
cases:6.59%
controls:1.77%
cases:11.03%
controls:4.27%
10
49
162
1671
9
30
163
1690
—
—
8
9
163
1709
11
30
156
1665
16
65
129
1457
Laceration/cut
S18 [2002000983]
S18 [2002000983]
5.6e-01
1.1e+00
—
—
2.8e+00
1.7e+00
5.8e-01
cases:8.72%
controls:5.17%
cases:6.98%
controls:2.33%
—
—
—
—
cases:4.68%
controls:0.29%
cases:9.58%
controls:1.83%
cases:11.03%
controls:6.50%
15
89
157
1631
12
40
160
1680
—
—
8
5
163
1713
16
31
151
1664
16
99
129
1423
enoxaparin; parenteral
B01AB05 [21600976]
B01AB05 [21600976]
8.9e-01
2.0e+00
—
—
1.0e+50
2.4e+00
1.2e+00
cases:7.56%
controls:3.26%
cases:5.81%
controls:0.81%
—
—
—
—
cases:4.68%
controls:0.00%
cases:11.38%
controls:1.18%
cases:8.28%
controls:2.63%
13
56
159
1664
10
14
162
1706
—
—
8
0
163
1718
19
20
148
1675
12
40
133
1482
ibuprofen
R02AX02 [1588667]
R02AX02 [1588667]
4.6e-01
5.6e-01
1.7e+00
—
1.9e+00
7.8e-01
7.7e-02
cases:40.70%
controls:30.17%
cases:20.93%
controls:13.14%
cases:6.98%
controls:1.40%
—
—
cases:11.70%
controls:1.86%
cases:23.95%
controls:12.63%
cases:35.17%
controls:33.44%
70
519
102
1201
36
226
136
1494
12
24
160
1696
—
20
32
151
1686
40
214
127
1481
51
509
94
1013
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
M01AE01 [21603967]
4.6e-01
5.6e-01
1.7e+00
—
1.9e+00
7.8e-01
7.7e-02
cases:40.70%
controls:30.17%
cases:20.93%
controls:13.14%
cases:6.98%
controls:1.40%
—
—
cases:11.70%
controls:1.86%
cases:23.95%
controls:12.63%
cases:35.17%
controls:33.44%
70
519
102
1201
36
226
136
1494
12
24
160
1696
—
20
32
151
1686
40
214
127
1481
51
509
94
1013
Case Management Agency
251B00000X [38004193]
251B00000X [38004193]
2.8e-01
3.1e-01
5.6e-01
3.7e+00
6.4e-01
4.2e-01
3.0e-01
cases:54.07%
controls:47.03%
cases:46.51%
controls:38.95%
cases:24.42%
controls:15.52%
cases:21.51%
controls:0.64%
cases:27.49%
controls:16.71%
cases:54.49%
controls:43.95%
cases:71.03%
controls:64.45%
93
809
79
911
80
670
92
1050
42
267
130
1453
37
11
135
1709
47
287
124
1431
91
745
76
950
103
981
42
541
More than one and less than three hours
ZXE10 [2001311401]
ZXE10 [2001311401]
3.4e-01
1.5e+00
—
—
—
1.8e+00
9.9e-01
cases:6.40%
controls:4.65%
cases:6.40%
controls:1.45%
—
—
—
—
—
—
cases:6.59%
controls:1.12%
cases:11.03%
controls:4.40%
11
80
161
1640
11
25
161
1695
—
—
—
11
19
156
1676
16
67
129
1455
Physical Medicine And Rehabilitation
25 [38004468]
25 [38004468]
7.1e-01
8.7e-01
—
—
2.5e+00
1.7e+00
6.3e-01
cases:8.72%
controls:4.48%
cases:4.07%
controls:1.74%
—
—
—
—
cases:4.09%
controls:0.35%
cases:9.58%
controls:1.83%
cases:12.41%
controls:7.03%
15
77
157
1643
7
30
165
1690
—
—
7
6
164
1712
16
31
151
1664
18
107
127
1415
Plastic And Reconstructive Surgery
24 [38004467]
24 [38004467]
1.3e+00
1.3e+00
—
1.0e+50
—
2.8e+00
1.1e+00
cases:6.98%
controls:2.03%
cases:3.49%
controls:0.99%
—
—
cases:5.23%
controls:0.00%
—
—
cases:14.97%
controls:1.06%
cases:8.28%
controls:2.89%
12
35
160
1685
6
17
166
1703
—
9
0
163
1720
—
25
18
142
1677
12
44
133
1478
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
1995-0 [3021347]
2.4e-01
7.0e-01
2.0e+00
—
2.0e+00
9.1e-01
4.9e-01
cases:6.98%
controls:5.58%
cases:5.81%
controls:2.97%
cases:3.49%
controls:0.47%
—
—
cases:4.09%
controls:0.58%
cases:8.38%
controls:3.54%
cases:13.10%
controls:8.48%
12
96
160
1624
10
51
162
1669
6
8
166
1712
—
7
10
164
1708
14
60
153
1635
19
129
126
1393
Physiotherapist
Z3226 [2001311560]
Z3226 [2001311560]
7.4e-01
1.7e+00
—
1.0e+50
—
2.4e+00
1.4e+00
cases:5.23%
controls:2.56%
cases:4.07%
controls:0.76%
—
—
cases:5.23%
controls:0.00%
—
—
cases:8.98%
controls:0.88%
cases:6.90%
controls:1.77%
9
44
163
1676
7
13
165
1707
—
9
0
163
1720
—
15
15
152
1680
10
27
135
1495
Erysipelas
A46 [45561706]
A46 [45561706]
9.1e-01
2.0e+00
—
—
—
2.4e+00
1.4e+00
cases:4.65%
controls:1.92%
cases:2.91%
controls:0.41%
—
—
—
—
—
—
cases:6.59%
controls:0.65%
cases:8.97%
controls:2.30%
8
33
164
1687
5
7
167
1713
—
—
—
11
11
156
1684
13
35
132
1487
Supplier / Service Provider
OMOP5117446 [33004]
OMOP5117446 [33004]
-1.1e+00
-1.4e-01
—
—
—
2.2e+00
2.7e+00
cases:10.47%
controls:26.05%
cases:5.23%
controls:5.99%
—
—
—
—
—
—
cases:3.59%
controls:0.41%
cases:9.66%
controls:0.72%
18
448
154
1272
9
103
163
1617
—
—
—
6
7
161
1688
14
11
131
1511
Bacteria identified in Isolate by Culture
43409-2 [3042936]
43409-2 [3042936]
8.2e-01
—
—
—
—
2.1e+00
1.5e+00
cases:3.49%
controls:1.57%
—
—
—
—
—
—
—
—
cases:4.79%
controls:0.59%
cases:8.28%
controls:1.91%
6
27
166
1693
—
—
—
—
8
10
159
1685
12
29
133
1493
General anesthesia, balanced
WX408 [2001310808]
WX408 [2001310808]
7.0e-01
1.9e+00
—
1.0e+50
1.0e+50
—
1.7e+00
cases:5.23%
controls:2.67%
cases:5.23%
controls:0.81%
—
—
cases:4.65%
controls:0.00%
cases:3.51%
controls:0.00%
—
—
cases:10.34%
controls:1.97%
9
46
163
1674
9
14
163
1706
—
8
0
164
1720
6
0
165
1718
—
15
30
130
1492
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
19072-8 [3016431]
2.3e-01
6.5e-01
2.0e+00
—
1.7e+00
1.2e+00
4.2e-01
cases:7.56%
controls:6.10%
cases:6.40%
controls:3.43%
cases:3.49%
controls:0.47%
—
—
cases:4.09%
controls:0.76%
cases:11.38%
controls:3.72%
cases:14.48%
controls:9.99%
13
105
159
1615
11
59
161
1661
6
8
166
1712
—
7
13
164
1705
19
63
148
1632
21
152
124
1370
Urgent procedure
ZXD05 [2001311386]
ZXD05 [2001311386]
3.9e-01
1.8e+00
—
—
—
1.3e+00
1.3e+00
cases:5.81%
controls:4.01%
cases:4.65%
controls:0.81%
—
—
—
—
—
—
cases:4.19%
controls:1.18%
cases:11.03%
controls:3.22%
10
69
162
1651
8
14
164
1706
—
—
—
7
20
160
1675
16
49
129
1473
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
1988-5 [3020460]
9.3e-02
2.6e-01
1.8e+00
1.0e+50
1.2e+00
6.5e-01
3.1e-01
cases:19.19%
controls:17.79%
cases:15.70%
controls:12.56%
cases:9.88%
controls:1.80%
cases:11.05%
controls:0.00%
cases:10.53%
controls:3.32%
cases:20.96%
controls:12.15%
cases:34.48%
controls:27.86%
33
306
139
1414
27
216
145
1504
17
31
155
1689
19
0
153
1720
18
57
153
1661
35
206
132
1489
50
424
95
1098
CBC panel - Blood by Automated count
58410-2 [40761511]
58410-2 [40761511]
-5.3e-02
2.7e-01
1.4e+00
—
1.6e+00
6.4e-01
1.8e-01
cases:18.60%
controls:19.42%
cases:16.28%
controls:12.97%
cases:8.14%
controls:2.09%
—
—
cases:11.11%
controls:2.50%
cases:21.56%
controls:12.63%
cases:33.79%
controls:29.83%
32
334
140
1386
28
223
144
1497
14
36
158
1684
—
19
43
152
1675
36
214
131
1481
49
454
96
1068
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
J01MA12 [21603019]
1.5e+00
—
—
—
—
—
1.4e+00
cases:6.40%
controls:1.45%
—
—
—
—
—
—
—
—
—
—
cases:7.59%
controls:1.97%
11
25
161
1695
—
—
—
—
—
11
30
134
1492
Right side
ZXA00 [2001311346]
ZXA00 [2001311346]
8.3e-01
1.3e+00
—
1.0e+50
—
2.9e+00
7.1e-01
cases:5.81%
controls:2.62%
cases:3.49%
controls:0.93%
—
—
cases:2.91%
controls:0.00%
—
—
cases:5.99%
controls:0.35%
cases:6.21%
controls:3.15%
10
45
162
1675
6
16
166
1704
—
5
0
167
1720
—
10
6
157
1689
9
48
136
1474
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
890-4 [3001079]
5.3e-01
9.2e-01
—
1.0e+50
2.9e+00
6.7e-01
7.8e-01
cases:7.56%
controls:4.59%
cases:5.23%
controls:2.15%
—
—
cases:5.81%
controls:0.00%
cases:5.85%
controls:0.35%
cases:4.19%
controls:2.18%
cases:12.41%
controls:6.11%
13
79
159
1641
9
37
163
1683
—
10
0
162
1720
10
6
161
1712
7
37
160
1658
18
93
127
1429
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2823-3 [3023103]
-7.3e-03
1.4e-01
1.3e+00
—
1.4e+00
3.2e-01
2.1e-01
cases:19.77%
controls:19.88%
cases:17.44%
controls:15.47%
cases:8.14%
controls:2.38%
—
—
cases:12.87%
controls:3.49%
cases:21.56%
controls:16.70%
cases:36.55%
controls:31.73%
34
342
138
1378
30
266
142
1454
14
41
158
1679
—
22
60
149
1658
36
283
131
1412
53
483
92
1039
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2951-2 [3019550]
3.7e-03
1.7e-01
1.3e+00
—
1.4e+00
3.5e-01
2.1e-01
cases:19.77%
controls:19.71%
cases:17.44%
controls:15.12%
cases:8.14%
controls:2.38%
—
—
cases:12.87%
controls:3.49%
cases:21.56%
controls:16.17%
cases:36.55%
controls:31.73%
34
339
138
1381
30
260
142
1460
14
41
158
1679
—
22
60
149
1658
36
274
131
1421
53
483
92
1039
Treatment of reopened or infected surgical wound
SPAT1144 [2001700245]
SPAT1144 [2001700245]
—
—
—
—
—
1.0e+50
2.5e+00
—
—
—
—
—
—
—
—
—
—
cases:2.99%
controls:0.00%
cases:4.83%
controls:0.39%
—
—
—
—
—
5
0
162
1695
7
6
138
1516
lorazepam; oral, parenteral, sublingual
N05BA06 [21604571]
N05BA06 [21604571]
—
—
—
—
—
2.5e+00
1.9e+00
—
—
—
—
—
—
—
—
—
—
cases:3.59%
controls:0.29%
cases:3.45%
controls:0.53%
—
—
—
—
—
6
5
161
1690
5
8
140
1514
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
5894-1 [3033658]
—
2.5e-01
—
1.0e+50
2.5e+00
6.5e-01
5.8e-01
—
—
cases:2.91%
controls:2.27%
—
—
cases:3.49%
controls:0.00%
cases:3.51%
controls:0.29%
cases:5.39%
controls:2.89%
cases:7.59%
controls:4.40%
—
5
39
167
1681
—
6
0
166
1720
6
5
165
1713
9
49
158
1646
11
67
134
1455
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
2019-8 [3027946]
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
cases:4.19%
controls:0.35%
—
—
—
—
—
—
—
7
6
160
1689
—
pH of Arterial blood
2744-1 [3019977]
2744-1 [3019977]
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
cases:4.19%
controls:0.35%
—
—
—
—
—
—
—
7
6
160
1689
—
Oxygen [Partial pressure] in Arterial blood
2703-7 [3027801]
2703-7 [3027801]
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
cases:4.19%
controls:0.35%
—
—
—
—
—
—
—
7
6
160
1689
—
Internal Medicine
11 [38004456]
11 [38004456]
3.1e-01
7.8e-01
1.1e+00
1.0e+50
1.5e+00
9.1e-01
8.0e-01
cases:26.74%
controls:21.16%
cases:16.28%
controls:8.20%
cases:5.23%
controls:1.80%
cases:2.91%
controls:0.00%
cases:4.68%
controls:1.05%
cases:20.36%
controls:9.32%
cases:33.79%
controls:18.73%
46
364
126
1356
28
141
144
1579
9
31
163
1689
5
0
167
1720
8
18
163
1700
34
158
133
1537
49
285
96
1237
Bacteria identified in Skin by Aerobe culture
620-5 [3007853]
620-5 [3007853]
—
1.9e+00
—
—
—
2.4e+00
—
—
—
cases:2.91%
controls:0.47%
—
—
—
—
—
—
cases:4.19%
controls:0.41%
—
—
—
5
8
167
1712
—
—
—
7
7
160
1688
—
Base excess in Arterial blood by calculation
1925-7 [3003396]
1925-7 [3003396]
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
cases:3.59%
controls:0.35%
—
—
—
—
—
—
—
6
6
161
1689
—
Feeling anxious/nervous/tense
P01 [2002000798]
P01 [2002000798]
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
cases:3.59%
controls:0.35%
—
—
—
—
—
—
—
6
6
161
1689
—
Pulmonary Disease
29 [38004472]
29 [38004472]
4.7e-01
7.5e-01
—
—
2.3e+00
8.7e-01
5.3e-01
cases:10.47%
controls:6.80%
cases:6.40%
controls:3.14%
—
—
—
—
cases:2.92%
controls:0.29%
cases:7.19%
controls:3.13%
cases:12.41%
controls:7.69%
18
117
154
1603
11
54
161
1666
—
—
5
5
166
1713
12
53
155
1642
18
117
127
1405
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
14682-9 [3020564]
-3.2e-02
7.5e-02
1.1e+00
—
1.2e+00
2.4e-01
1.2e-01
cases:20.35%
controls:20.87%
cases:18.60%
controls:17.50%
cases:9.30%
controls:3.20%
—
—
cases:12.87%
controls:4.42%
cases:22.75%
controls:18.88%
cases:37.93%
controls:35.22%
35
359
137
1361
32
301
140
1419
16
55
156
1665
—
22
76
149
1642
38
320
129
1375
55
536
90
986
clindamycin; oral, parenteral
J01FF01 [21602985]
J01FF01 [21602985]
1.1e+00
1.3e+00
—
—
—
—
1.1e+00
cases:8.72%
controls:2.97%
cases:3.49%
controls:0.93%
—
—
—
—
—
—
—
—
cases:10.34%
controls:3.55%
15
51
157
1669
6
16
166
1704
—
—
—
—
15
54
130
1468
Ultrasound examination of lower leg veins
PH2AE [2001309451]
PH2AE [2001309451]
—
—
—
1.0e+50
—
2.2e+00
1.7e+00
—
—
—
—
—
—
cases:5.81%
controls:0.00%
—
—
cases:4.79%
controls:0.53%
cases:4.83%
controls:0.92%
—
—
—
10
0
162
1720
—
8
9
159
1686
7
14
138
1508
pantoprazole; oral, parenteral
A02BC02 [21600097]
A02BC02 [21600097]
5.9e-01
1.1e+00
—
—
6.5e-01
1.1e+00
5.9e-01
cases:22.09%
controls:13.55%
cases:18.02%
controls:6.98%
—
—
—
—
cases:3.51%
controls:1.86%
cases:21.56%
controls:8.02%
cases:25.52%
controls:15.97%
38
233
134
1487
31
120
141
1600
—
—
6
32
165
1686
36
136
131
1559
37
243
108
1279
Atrial fibrillation/flutter
K78 [2002000605]
K78 [2002000605]
2.2e+00
—
—
—
—
—
—
cases:4.07%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
7
8
165
1712
—
—
—
—
—
—
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
GD1UA [2001303652]
9.4e-01
2.2e+00
—
—
—
1.6e+00
1.1e+00
cases:3.49%
controls:1.40%
cases:4.07%
controls:0.47%
—
—
—
—
—
—
cases:2.99%
controls:0.59%
cases:4.14%
controls:1.45%
6
24
166
1696
7
8
165
1712
—
—
—
5
10
162
1685
6
22
139
1500
Other diagnostic examination of periferal vessel
XPX99 [2001309755]
XPX99 [2001309755]
—
—
—
—
—
2.1e+00
1.4e+00
—
—
—
—
—
—
—
—
—
—
cases:4.79%
controls:0.59%
cases:3.45%
controls:0.85%
—
—
—
—
—
8
10
159
1685
5
13
140
1509
oxycodone and naloxone; oral
N02AA55 [21604265]
N02AA55 [21604265]
—
—
—
—
—
2.1e+00
1.3e+00
—
—
—
—
—
—
—
—
—
—
cases:4.79%
controls:0.59%
cases:6.21%
controls:1.71%
—
—
—
—
—
8
10
159
1685
9
26
136
1496
Measurement of mechanical axis of lower leg with X-ray
NJ2MA [2001308419]
NJ2MA [2001308419]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.14%
controls:0.53%
—
—
—
—
—
—
6
8
139
1514
Spinalanesthesia
WX320 [2001310799]
WX320 [2001310799]
6.0e-01
—
—
—
—
2.1e+00
7.5e-01
cases:4.07%
controls:2.27%
—
—
—
—
—
—
—
—
cases:6.59%
controls:0.88%
cases:6.21%
controls:3.02%
7
39
165
1681
—
—
—
—
11
15
156
1680
9
46
136
1476
Counselling/guidance promoting independent living
SPAT1222 [2001700323]
SPAT1222 [2001700323]
—
-1.0e+50
—
—
—
2.1e+00
1.0e+00
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
cases:3.59%
controls:0.47%
cases:4.14%
controls:1.51%
—
0
6
172
1714
—
—
—
6
8
161
1687
6
23
139
1499
Platelets [#/volume] in Blood
26515-7 [3007461]
26515-7 [3007461]
-4.0e-02
4.5e-02
1.1e+00
—
9.9e-01
2.8e-01
1.2e-01
cases:22.09%
controls:22.79%
cases:19.77%
controls:19.07%
cases:10.47%
controls:3.90%
—
—
cases:13.45%
controls:5.47%
cases:24.55%
controls:19.76%
cases:40.69%
controls:37.91%
38
392
134
1328
34
328
138
1392
18
67
154
1653
—
23
94
148
1624
41
335
126
1360
59
577
86
945
Nephrology
39 [38004479]
39 [38004479]
2.0e+00
1.9e+00
—
—
—
2.0e+00
1.3e+00
cases:3.49%
controls:0.47%
cases:2.91%
controls:0.47%
—
—
—
—
—
—
cases:2.99%
controls:0.41%
cases:3.45%
controls:0.92%
6
8
166
1712
5
8
167
1712
—
—
—
5
7
162
1688
5
14
140
1508
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
30428-7 [3024731]
-4.0e-02
4.8e-02
1.1e+00
—
9.8e-01
2.8e-01
1.1e-01
cases:22.09%
controls:22.79%
cases:19.77%
controls:19.01%
cases:10.47%
controls:3.90%
—
—
cases:13.45%
controls:5.53%
cases:24.55%
controls:19.71%
cases:40.69%
controls:38.04%
38
392
134
1328
34
327
138
1393
18
67
154
1653
—
23
95
148
1623
41
334
126
1361
59
579
86
943
Leukocytes [#/volume] in Blood
26464-8 [3010813]
26464-8 [3010813]
-4.0e-02
4.5e-02
1.1e+00
—
9.8e-01
2.8e-01
1.4e-01
cases:22.09%
controls:22.79%
cases:19.77%
controls:19.07%
cases:10.47%
controls:3.90%
—
—
cases:13.45%
controls:5.53%
cases:24.55%
controls:19.71%
cases:41.38%
controls:38.04%
38
392
134
1328
34
328
138
1392
18
67
154
1653
—
23
95
148
1623
41
334
126
1361
60
579
85
943
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
20570-8 [3009542]
-4.3e-02
4.1e-02
1.1e+00
—
9.8e-01
2.8e-01
1.1e-01
cases:22.09%
controls:22.85%
cases:19.77%
controls:19.13%
cases:10.47%
controls:3.90%
—
—
cases:13.45%
controls:5.53%
cases:24.55%
controls:19.71%
cases:40.69%
controls:38.04%
38
393
134
1327
34
329
138
1391
18
67
154
1653
—
23
95
148
1623
41
334
126
1361
59
579
86
943
MCH [Entitic mass]
28539-5 [3035941]
28539-5 [3035941]
-2.7e-02
4.5e-02
1.1e+00
—
9.8e-01
2.9e-01
1.1e-01
cases:22.09%
controls:22.56%
cases:19.77%
controls:19.07%
cases:10.47%
controls:3.90%
—
—
cases:13.45%
controls:5.53%
cases:24.55%
controls:19.65%
cases:40.69%
controls:38.04%
38
388
134
1332
34
328
138
1392
18
67
154
1653
—
23
95
148
1623
41
333
126
1362
59
579
86
943
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
26453-1 [3026361]
-4.3e-02
4.1e-02
1.1e+00
—
9.8e-01
2.8e-01
1.1e-01
cases:22.09%
controls:22.85%
cases:19.77%
controls:19.13%
cases:10.47%
controls:3.90%
—
—
cases:13.45%
controls:5.53%
cases:24.55%
controls:19.71%
cases:40.69%
controls:38.04%
38
393
134
1327
34
329
138
1391
18
67
154
1653
—
23
95
148
1623
41
334
126
1361
59
579
86
943
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
718-7 [3000963]
-4.3e-02
3.3e-02
1.0e+00
—
9.8e-01
2.7e-01
1.1e-01
cases:22.09%
controls:22.85%
cases:19.77%
controls:19.24%
cases:10.47%
controls:3.95%
—
—
cases:13.45%
controls:5.53%
cases:24.55%
controls:19.82%
cases:40.69%
controls:38.11%
38
393
134
1327
34
331
138
1389
18
68
154
1652
—
23
95
148
1623
41
336
126
1359
59
580
86
942
Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
34487-9 [3044938]
34487-9 [3044938]
—
2.0e+00
—
—
—
1.3e+00
—
—
—
cases:4.07%
controls:0.58%
—
—
—
—
—
—
cases:2.99%
controls:0.83%
—
—
—
7
10
165
1710
—
—
—
5
14
162
1681
—
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
2601-3 [3012095]
8.7e-01
2.0e+00
—
—
1.0e+50
1.3e+00
6.1e-01
cases:4.07%
controls:1.74%
cases:4.07%
controls:0.58%
—
—
—
—
cases:2.92%
controls:0.00%
cases:4.19%
controls:1.12%
cases:4.14%
controls:2.30%
7
30
165
1690
7
10
165
1710
—
—
5
0
166
1718
7
19
160
1676
6
35
139
1487
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Blood
47598-8 [3048816]
47598-8 [3048816]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.21%
controls:0.92%
—
—
—
—
—
—
9
14
136
1508
Partial excision of meniscus of knee, arthroscopic
NGD05 [2001308109]
NGD05 [2001308109]
—
1.0e+50
—
1.0e+50
—
—
1.9e+00
—
—
cases:4.65%
controls:0.00%
—
—
cases:4.07%
controls:0.00%
—
—
—
—
cases:4.83%
controls:0.72%
—
8
0
164
1720
—
7
0
165
1720
—
—
7
11
138
1511
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
14749-6 [3013826]
1.9e-01
3.2e-01
1.9e+00
1.0e+50
1.6e+00
9.5e-01
2.1e-01
cases:9.30%
controls:7.85%
cases:4.65%
controls:3.43%
cases:4.07%
controls:0.64%
cases:9.30%
controls:0.00%
cases:3.51%
controls:0.70%
cases:9.58%
controls:3.95%
cases:13.79%
controls:11.50%
16
135
156
1585
8
59
164
1661
7
11
165
1709
16
0
156
1720
6
12
165
1706
16
67
151
1628
20
175
125
1347
Supine thorax X-ray examination
GD1QA [2001303648]
GD1QA [2001303648]
1.1e+00
1.9e+00
—
—
—
1.7e+00
5.0e-01
cases:3.49%
controls:1.22%
cases:4.07%
controls:0.64%
—
—
—
—
—
—
cases:4.19%
controls:0.77%
cases:4.14%
controls:2.56%
6
21
166
1699
7
11
165
1709
—
—
—
7
13
160
1682
6
39
139
1483
Other primary gonarthrosis
M17.1 [45596493]
M17.1 [45596493]
1.1e+00
—
—
—
—
1.9e+00
1.1e+00
cases:5.81%
controls:2.03%
—
—
—
—
—
—
—
—
cases:5.39%
controls:0.88%
cases:6.90%
controls:2.50%
10
35
162
1685
—
—
—
—
9
15
158
1680
10
38
135
1484
Atherosclerosis of arteries of extremities
I70.2 [45538421]
I70.2 [45538421]
7.9e-01
1.4e+00
—
—
—
1.8e+00
1.3e+00
cases:2.91%
controls:1.34%
cases:2.91%
controls:0.76%
—
—
—
—
—
—
cases:5.99%
controls:1.00%
cases:5.52%
controls:1.64%
5
23
167
1697
5
13
167
1707
—
—
—
10
17
157
1678
8
25
137
1497
Scheduled procedure
ZXD10 [2001311387]
ZXD10 [2001311387]
5.7e-01
—
—
—
—
1.8e+00
7.7e-01
cases:7.56%
controls:4.42%
—
—
—
—
—
—
—
—
cases:6.59%
controls:1.12%
cases:10.34%
controls:5.06%
13
76
159
1644
—
—
—
—
11
19
156
1676
15
77
130
1445
Heart failure, unspecified
I50.9 [45576879]
I50.9 [45576879]
7.8e-01
1.5e+00
—
—
—
1.8e+00
7.4e-01
cases:3.49%
controls:1.63%
cases:3.49%
controls:0.81%
—
—
—
—
—
—
cases:4.19%
controls:0.71%
cases:4.83%
controls:2.37%
6
28
166
1692
6
14
166
1706
—
—
—
7
12
160
1683
7
36
138
1486
Implementation of physical therapy rehabilitation plan
SPAT1223 [2001700324]
SPAT1223 [2001700324]
9.0e-02
—
—
—
—
1.8e+00
9.3e-01
cases:3.49%
controls:3.20%
—
—
—
—
—
—
—
—
cases:5.39%
controls:0.94%
cases:8.97%
controls:3.75%
6
55
166
1665
—
—
—
—
9
16
158
1679
13
57
132
1465
Iron/Transferrin [Ratio] in Serum or Plasma
60517-0 [40763571]
60517-0 [40763571]
9.3e-01
—
—
—
—
1.7e+00
1.2e+00
cases:2.91%
controls:1.16%
—
—
—
—
—
—
—
—
cases:4.79%
controls:0.88%
cases:8.28%
controls:2.69%
5
20
167
1700
—
—
—
—
8
15
159
1680
12
41
133
1481
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
3034-6 [3004789]
1.0e+00
—
—
—
—
1.7e+00
1.1e+00
cases:3.49%
controls:1.28%
—
—
—
—
—
—
—
—
cases:4.79%
controls:0.88%
cases:8.28%
controls:2.96%
6
22
166
1698
—
—
—
—
8
15
159
1680
12
45
133
1477
benzathine phenoxymethylpenicillin; oral
J01CE10 [21602850]
J01CE10 [21602850]
6.9e-01
1.0e+00
-1.0e+50
—
—
5.1e-01
3.7e-01
cases:23.26%
controls:13.20%
cases:8.72%
controls:3.31%
cases:0.00%
controls:0.64%
—
—
—
—
cases:6.59%
controls:4.07%
cases:17.93%
controls:13.14%
40
227
132
1493
15
57
157
1663
0
11
172
1709
—
—
11
69
156
1626
26
200
119
1322
phenoxymethylpenicillin; oral
J01CE02 [21602842]
J01CE02 [21602842]
6.9e-01
1.0e+00
-1.0e+50
—
—
5.1e-01
3.7e-01
cases:23.26%
controls:13.20%
cases:8.72%
controls:3.31%
cases:0.00%
controls:0.64%
—
—
—
—
cases:6.59%
controls:4.07%
cases:17.93%
controls:13.14%
40
227
132
1493
15
57
157
1663
0
11
172
1709
—
—
11
69
156
1626
26
200
119
1322
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
R5110 [2001310246]
R5110 [2001310246]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.52%
controls:1.05%
—
—
—
—
—
—
8
16
137
1506
Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]
14798-3 [3022948]
1.1e+00
1.4e+00
—
—
—
1.7e+00
9.8e-01
cases:3.49%
controls:1.22%
cases:2.91%
controls:0.76%
—
—
—
—
—
—
cases:4.79%
controls:0.94%
cases:8.28%
controls:3.29%
6
21
166
1699
5
13
167
1707
—
—
—
8
16
159
1679
12
50
133
1472
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
J01MA02 [21603009]
2.2e-01
7.5e-01
—
—
—
1.6e+00
5.0e-01
cases:7.56%
controls:6.16%
cases:2.91%
controls:1.40%
—
—
—
—
—
—
cases:6.59%
controls:1.36%
cases:8.97%
controls:5.65%
13
106
159
1614
5
24
167
1696
—
—
—
11
23
156
1672
13
86
132
1436
Urea [Moles/volume] in Serum or Plasma
22664-7 [3020779]
22664-7 [3020779]
—
—
—
—
—
1.3e+00
1.5e+00
—
—
—
—
—
—
—
—
—
—
cases:2.99%
controls:0.83%
cases:6.90%
controls:1.64%
—
—
—
—
—
5
14
162
1681
10
25
135
1497
Pain in limb
M79.6 [45587063]
M79.6 [45587063]
1.9e-01
7.5e-01
—
—
—
1.5e+00
7.9e-01
cases:4.65%
controls:3.90%
cases:2.91%
controls:1.40%
—
—
—
—
—
—
cases:7.78%
controls:1.89%
cases:13.79%
controls:6.77%
8
67
164
1653
5
24
167
1696
—
—
—
13
32
154
1663
20
103
125
1419
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
N02BE01 [21604344]
3.2e-01
6.2e-01
5.3e-01
—
5.9e-01
7.2e-01
7.1e-01
cases:31.40%
controls:24.88%
cases:22.09%
controls:13.26%
cases:4.65%
controls:2.79%
—
—
cases:5.85%
controls:3.32%
cases:26.95%
controls:15.16%
cases:48.28%
controls:31.47%
54
428
118
1292
38
228
134
1492
8
48
164
1672
—
10
57
161
1661
45
257
122
1438
70
479
75
1043
Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]
30248-9 [3015399]
2.1e-02
1.1e+00
—
—
—
1.4e+00
2.8e-01
cases:2.91%
controls:2.85%
cases:4.07%
controls:1.34%
—
—
—
—
—
—
cases:7.19%
controls:1.83%
cases:6.90%
controls:5.32%
5
49
167
1671
7
23
165
1697
—
—
—
12
31
155
1664
10
81
135
1441
Inpatient Visit
IP [9201]
IP [9201]
2.6e-01
1.1e+00
—
—
—
1.4e+00
1.2e-01
cases:5.23%
controls:4.07%
cases:3.49%
controls:1.22%
—
—
—
—
—
—
cases:8.38%
controls:2.24%
cases:5.52%
controls:4.93%
9
70
163
1650
6
21
166
1699
—
—
—
14
38
153
1657
8
75
137
1447
No procedures
SPAT1301 [2001700402]
SPAT1301 [2001700402]
-3.2e-01
8.6e-01
-1.0e+50
—
—
1.4e+00
7.1e-01
cases:2.91%
controls:3.95%
cases:3.49%
controls:1.51%
cases:0.00%
controls:0.29%
—
—
—
—
cases:6.59%
controls:1.77%
cases:8.97%
controls:4.60%
5
68
167
1652
6
26
166
1694
0
5
172
1715
—
—
11
30
156
1665
13
70
132
1452
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
6598-7 [3019800]
4.6e-01
8.5e-01
—
1.0e+50
—
1.3e+00
4.6e-01
cases:6.98%
controls:4.53%
cases:4.65%
controls:2.03%
—
—
cases:4.65%
controls:0.00%
—
—
cases:6.59%
controls:1.83%
cases:9.66%
controls:6.31%
12
78
160
1642
8
35
164
1685
—
8
0
164
1720
—
11
31
156
1664
14
96
131
1426
amoxicillin; oral, parenteral
J01CA04 [21602823]
J01CA04 [21602823]
6.4e-01
2.2e-01
—
—
-1.0e+50
-1.3e-01
6.9e-01
cases:31.98%
controls:19.94%
cases:8.14%
controls:6.63%
—
—
—
—
cases:0.00%
controls:0.70%
cases:5.39%
controls:6.08%
cases:31.03%
controls:18.40%
55
343
117
1377
14
114
158
1606
—
—
0
12
171
1706
9
103
158
1592
45
280
100
1242
Acute bronchitis, unspecified
J20.9 [45562445]
J20.9 [45562445]
1.0e+00
—
—
—
—
-1.0e+50
1.3e+00
cases:4.65%
controls:1.69%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
cases:8.28%
controls:2.37%
8
29
164
1691
—
—
—
—
0
6
167
1689
12
36
133
1486
allopurinol; oral, parenteral
M04AA01 [21604131]
M04AA01 [21604131]
9.8e-01
1.4e+00
—
—
—
1.3e+00
9.9e-01
cases:6.40%
controls:2.50%
cases:5.81%
controls:1.57%
—
—
—
—
—
—
cases:6.59%
controls:1.89%
cases:7.59%
controls:2.96%
11
43
161
1677
10
27
162
1693
—
—
—
11
32
156
1663
11
45
134
1477
Pharmacy visit
OMOP4822462 [581458]
OMOP4822462 [581458]
1.2e+00
7.3e-01
6.0e-01
9.5e-01
6.8e-01
8.4e-01
1.1e+00
cases:97.09%
controls:91.28%
cases:89.53%
controls:80.41%
cases:55.23%
controls:40.47%
cases:5.81%
controls:2.33%
cases:56.73%
controls:39.81%
cases:89.82%
controls:79.23%
cases:97.93%
controls:94.28%
167
1570
5
150
154
1383
18
337
95
696
77
1024
10
40
162
1680
97
684
74
1034
150
1343
17
352
142
1435
3
87
Medical doctor
Z2221 [2001311556]
Z2221 [2001311556]
4.4e-01
1.2e+00
—
—
—
1.2e+00
1.2e+00
cases:5.81%
controls:3.84%
cases:3.49%
controls:1.10%
—
—
—
—
—
—
cases:4.19%
controls:1.24%
cases:8.97%
controls:2.83%
10
66
162
1654
6
19
166
1701
—
—
—
7
21
160
1674
13
43
132
1479
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
30383-4 [3000850]
—
—
—
—
—
1.4e+00
1.2e+00
—
—
—
—
—
—
—
—
—
—
cases:3.59%
controls:0.88%
cases:8.97%
controls:2.83%
—
—
—
—
—
6
15
161
1680
13
43
132
1479
Thorax X-ray examination
GD1AA [2001303617]
GD1AA [2001303617]
5.7e-01
1.1e+00
—
—
2.1e+00
1.1e+00
1.2e+00
cases:9.30%
controls:5.47%
cases:6.40%
controls:2.21%
—
—
—
—
cases:2.92%
controls:0.35%
cases:5.99%
controls:2.06%
cases:18.62%
controls:6.44%
16
94
156
1626
11
38
161
1682
—
—
5
6
166
1712
10
35
157
1660
27
98
118
1424
Home Visit
OMOP4822459 [581476]
OMOP4822459 [581476]
—
6.1e-01
-1.0e+50
—
1.2e+00
1.2e+00
3.4e-01
—
—
cases:3.49%
controls:1.92%
cases:0.00%
controls:0.47%
—
—
cases:2.92%
controls:0.87%
cases:7.78%
controls:2.48%
cases:8.97%
controls:6.57%
—
6
33
166
1687
0
8
172
1712
—
5
15
166
1703
13
42
154
1653
13
100
132
1422
Cardiology
6 [38004451]
6 [38004451]
3.7e-01
4.9e-01
1.6e+00
—
—
1.2e+00
6.2e-01
cases:10.47%
controls:7.50%
cases:5.23%
controls:3.26%
cases:2.91%
controls:0.58%
—
—
—
—
cases:10.18%
controls:3.30%
cases:13.79%
controls:7.95%
18
129
154
1591
9
56
163
1664
5
10
167
1710
—
—
17
56
150
1639
20
121
125
1401
Coloscopy
UJF32 [2001305029]
UJF32 [2001305029]
2.1e-02
—
—
—
—
—
1.2e+00
cases:2.91%
controls:2.85%
—
—
—
—
—
—
—
—
—
—
cases:8.97%
controls:2.89%
5
49
167
1671
—
—
—
—
—
13
44
132
1478
amitriptyline; oral, parenteral
N06AA09 [21604696]
N06AA09 [21604696]
—
—
—
—
—
1.7e+00
1.2e+00
—
—
—
—
—
—
—
—
—
—
cases:3.59%
controls:0.71%
cases:8.97%
controls:2.96%
—
—
—
—
—
6
12
161
1683
13
45
132
1477
Panorama tomography of teeth and jaws or similar X-ray examination
EB1HA [2001301913]
EB1HA [2001301913]
3.3e-01
—
—
—
—
—
1.2e+00
cases:5.81%
controls:4.24%
—
—
—
—
—
—
—
—
—
—
cases:13.79%
controls:4.73%
10
73
162
1647
—
—
—
—
—
20
72
125
1450
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
62238-1 [40764999]
0.0e+00
1.4e-01
1.1e+00
1.0e+50
1.2e+00
2.4e-01
2.6e-01
cases:15.12%
controls:15.12%
cases:14.53%
controls:12.91%
cases:7.56%
controls:2.67%
cases:11.05%
controls:0.00%
cases:9.94%
controls:3.32%
cases:17.37%
controls:14.22%
cases:28.97%
controls:23.85%
26
260
146
1460
25
222
147
1498
13
46
159
1674
19
0
153
1720
17
57
154
1661
29
241
138
1454
42
363
103
1159
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
14631-6 [3006140]
1.6e-01
6.5e-01
—
—
1.5e+00
1.2e+00
2.6e-01
cases:8.14%
controls:7.03%
cases:6.98%
controls:3.78%
—
—
—
—
cases:4.09%
controls:0.93%
cases:11.38%
controls:3.89%
cases:13.10%
controls:10.38%
14
121
158
1599
12
65
160
1655
—
—
7
16
164
1702
19
66
148
1629
19
158
126
1364
fluconazole; oral, parenteral
J02AC01 [21603080]
J02AC01 [21603080]
3.2e-01
—
—
—
—
1.0e+00
1.0e+00
cases:8.72%
controls:6.51%
—
—
—
—
—
—
—
—
cases:3.59%
controls:1.30%
cases:11.72%
controls:4.47%
15
112
157
1608
—
—
—
—
6
22
161
1673
17
68
128
1454
meloxicam; oral, parenteral, rectal
M01AC06 [21603965]
M01AC06 [21603965]
1.0e+00
8.6e-01
—
—
-1.0e+50
—
4.1e-01
cases:10.47%
controls:4.07%
cases:3.49%
controls:1.51%
—
—
—
—
cases:0.00%
controls:0.29%
—
—
cases:7.59%
controls:5.19%
18
70
154
1650
6
26
166
1694
—
—
0
5
171
1713
—
11
79
134
1443
zopiclone; oral
N05CF01 [21604654]
N05CF01 [21604654]
3.0e-01
7.1e-01
—
—
—
1.0e+00
6.8e-01
cases:9.30%
controls:7.09%
cases:8.14%
controls:4.19%
—
—
—
—
—
—
cases:10.18%
controls:3.95%
cases:13.79%
controls:7.49%
16
122
156
1598
14
72
158
1648
—
—
—
17
67
150
1628
20
114
125
1408
Normoblasts [#/volume] in Blood
715-3 [3021589]
715-3 [3021589]
1.0e-01
4.3e-01
1.3e+00
1.0e+50
1.2e+00
9.7e-01
4.6e-01
cases:6.40%
controls:5.81%
cases:6.98%
controls:4.65%
cases:4.65%
controls:1.28%
cases:4.65%
controls:0.00%
cases:3.51%
controls:1.05%
cases:12.57%
controls:5.19%
cases:13.79%
controls:9.20%
11
100
161
1620
12
80
160
1640
8
22
164
1698
8
0
164
1720
6
18
165
1700
21
88
146
1607
20
140
125
1382
Tissue Pathology biopsy report
66121-5 [40768804]
66121-5 [40768804]
0.0e+00
—
—
—
—
—
9.5e-01
cases:5.81%
controls:5.81%
—
—
—
—
—
—
—
—
—
—
cases:13.79%
controls:5.85%
10
100
162
1620
—
—
—
—
—
20
89
125
1433
Intramuscular and subcutaneous injection
SPAT1256 [2001700357]
SPAT1256 [2001700357]
6.4e-01
7.1e-01
—
—
—
7.6e-01
9.3e-01
cases:9.30%
controls:5.12%
cases:4.07%
controls:2.03%
—
—
—
—
—
—
cases:5.39%
controls:2.60%
cases:13.79%
controls:5.91%
16
88
156
1632
7
35
165
1685
—
—
—
9
44
158
1651
20
90
125
1432
Essential (primary) hypertension
I10 [45591453]
I10 [45591453]
2.1e-01
9.0e-01
1.6e+00
1.0e+50
1.1e+00
8.0e-01
3.5e-01
cases:14.53%
controls:12.15%
cases:12.79%
controls:5.64%
cases:4.07%
controls:0.81%
cases:3.49%
controls:0.00%
cases:2.92%
controls:0.99%
cases:13.77%
controls:6.73%
cases:22.07%
controls:16.69%
25
209
147
1511
22
97
150
1623
7
14
165
1706
6
0
166
1720
5
17
166
1701
23
114
144
1581
32
254
113
1268
Laboratory Visit
OMOP4822461 [32036]
OMOP4822461 [32036]
-1.8e-02
5.6e-02
8.6e-01
—
6.7e-01
1.2e-01
1.5e-01
cases:25.58%
controls:25.93%
cases:25.58%
controls:24.53%
cases:15.70%
controls:7.33%
—
—
cases:15.79%
controls:8.73%
cases:26.95%
controls:24.66%
cases:46.21%
controls:42.51%
44
446
128
1274
44
422
128
1298
27
126
145
1594
—
27
150
144
1568
45
418
122
1277
67
647
78
875
Upper gastrointestinal surgery
106 [44777669]
106 [44777669]
-2.1e-01
4.2e-02
—
—
-1.0e+50
8.8e-01
8.4e-01
cases:5.81%
controls:7.09%
cases:2.91%
controls:2.79%
—
—
—
—
cases:0.00%
controls:0.41%
cases:6.59%
controls:2.83%
cases:16.55%
controls:7.88%
10
122
162
1598
5
48
167
1672
—
—
0
7
171
1711
11
48
156
1647
24
120
121
1402
bisoprolol; oral
C07AB07 [21601689]
C07AB07 [21601689]
4.7e-01
6.9e-01
1.5e-01
—
—
7.3e-01
4.6e-01
cases:19.77%
controls:13.31%
cases:19.77%
controls:10.99%
cases:4.65%
controls:4.01%
—
—
—
—
cases:20.96%
controls:11.33%
cases:22.07%
controls:15.18%
34
229
138
1491
34
189
138
1531
8
69
164
1651
—
—
35
192
132
1503
32
231
113
1291
Swollen ankles/oedema
K07 [2002000550]
K07 [2002000550]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
172
1715
—
—
—
—
—
—
isosorbide mononitrate; oral
C01DA14 [21600324]
C01DA14 [21600324]
1.5e-01
—
—
—
—
—
2.2e-01
cases:3.49%
controls:3.02%
—
—
—
—
—
—
—
—
—
—
cases:4.14%
controls:3.35%
6
52
166
1668
—
—
—
—
—
6
51
139
1471
enalapril; oral, parenteral
C09AA02 [21601786]
C09AA02 [21601786]
6.0e-01
3.3e-01
—
—
—
2.9e-01
4.1e-01
cases:7.56%
controls:4.30%
cases:4.07%
controls:2.97%
—
—
—
—
—
—
cases:3.59%
controls:2.71%
cases:5.52%
controls:3.75%
13
74
159
1646
7
51
165
1669
—
—
—
6
46
161
1649
8
57
137
1465
celecoxib
L01XX33 [21603805]
L01XX33 [21603805]
8.6e-01
—
—
—
—
—
—
cases:3.49%
controls:1.51%
—
—
—
—
—
—
—
—
—
—
—
—
6
26
166
1694
—
—
—
—
—
—
Diabetic background retinopathy
H36.00 [2000502320]
H36.00 [2000502320]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
0
9
145
1513
Beta 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
32730-4 [3043723]
32730-4 [3043723]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
0
6
172
1714
—
—
—
—
—
Enthesopathy, unspecified
M77.9 [45591933]
M77.9 [45591933]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
5
145
1517
Intravenous sedation or analgesia without general anesthesia
WX006 [2001310762]
WX006 [2001310762]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
cases:0.00%
controls:0.53%
—
—
—
—
—
0
5
167
1690
0
8
145
1514
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
3016-3 [3009201]
4.5e-02
1.2e-01
—
—
—
-1.1e-01
-1.0e-01
cases:15.70%
controls:15.12%
cases:9.30%
controls:8.31%
—
—
—
—
—
—
cases:8.98%
controls:9.91%
cases:23.45%
controls:25.30%
27
260
145
1460
16
143
156
1577
—
—
—
15
168
152
1527
34
385
111
1137
Neutrophils [#/volume] in Blood
26499-4 [3017732]
26499-4 [3017732]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
0
6
172
1714
—
—
—
0
6
167
1689
—
Melanocytic naevi of trunk
D22.5 [45542688]
D22.5 [45542688]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
172
1715
—
—
—
—
—
—
hypromellose
S01KA02 [21605115]
S01KA02 [21605115]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
0
11
167
1684
—
Lyme disease
A69.2 [45595594]
A69.2 [45595594]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
0
8
145
1514
Other administrative function
SPAT1281 [2001700382]
SPAT1281 [2001700382]
-1.0e+50
—
—
—
—
—
1.7e+00
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
cases:3.45%
controls:0.66%
0
14
172
1706
—
—
—
—
—
5
10
140
1512
Delivery by emergency caesarean section
O82.10 [2000503217]
O82.10 [2000503217]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
6
145
1516
triamcinolone and antiinfectives
S02CA04 [21605176]
S02CA04 [21605176]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
172
1709
—
—
—
—
—
—
Cholesterol in HDL/Cholesterol.total [Molar ratio] in Serum or Plasma
70200-1 [42868674]
70200-1 [42868674]
—
—
—
—
—
-1.0e+50
8.9e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
cases:4.83%
controls:2.04%
—
—
—
—
—
0
13
167
1682
7
31
138
1491
Sprain and strain of cervical spine
S13.4 [45573197]
S13.4 [45573197]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
7
145
1515
Ultrasound examination of paranasal sinuses
SPAT1028 [2001700129]
SPAT1028 [2001700129]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.47%
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
0
8
172
1712
0
5
172
1715
—
—
—
—
—
Intraoral radiographic dental examination
EB1AA [2001301903]
EB1AA [2001301903]
6.4e-02
3.0e-01
—
—
—
4.9e-01
4.0e-01
cases:10.47%
controls:9.88%
cases:4.65%
controls:3.49%
—
—
—
—
—
—
cases:5.39%
controls:3.36%
cases:16.55%
controls:11.70%
18
170
154
1550
8
60
164
1660
—
—
—
9
57
158
1638
24
178
121
1344
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
1798-8 [3016771]
3.4e-01
—
—
—
—
1.4e+00
3.5e-01
cases:5.23%
controls:3.78%
—
—
—
—
—
—
—
—
cases:5.39%
controls:1.42%
cases:7.59%
controls:5.45%
9
65
163
1655
—
—
—
—
9
24
158
1671
11
83
134
1439
Treatment plan or consultation
WZC00 [2001310885]
WZC00 [2001310885]
4.8e-01
1.3e+00
—
—
—
1.4e+00
8.9e-01
cases:4.07%
controls:2.56%
cases:3.49%
controls:0.93%
—
—
—
—
—
—
cases:3.59%
controls:0.94%
cases:10.34%
controls:4.53%
7
44
165
1676
6
16
166
1704
—
—
—
6
16
161
1679
15
69
130
1453
Sampling
SPAT1263 [2001700364]
SPAT1263 [2001700364]
4.9e-01
6.4e-01
—
—
—
7.6e-01
4.7e-01
cases:8.72%
controls:5.52%
cases:4.65%
controls:2.50%
—
—
—
—
—
—
cases:5.39%
controls:2.60%
cases:11.72%
controls:7.69%
15
95
157
1625
8
43
164
1677
—
—
—
9
44
158
1651
17
117
128
1405
Cellulitis, unspecified
L03.9 [45581931]
L03.9 [45581931]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
5
145
1517
losartan and diuretics
C09DA01 [21601834]
C09DA01 [21601834]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
0
6
172
1714
—
—
—
—
Contact with and exposure to other communicable diseases
Z20.8 [45542410]
Z20.8 [45542410]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
cases:0.00%
controls:0.79%
—
—
—
—
—
0
7
167
1688
0
12
145
1510
Cervical disc disorder with radiculopathy
M50.1 [45596588]
M50.1 [45596588]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
0
12
145
1510
bimatoprost
S01EE03 [21603712]
S01EE03 [21603712]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.29%
cases:0.00%
controls:0.35%
—
—
—
—
—
—
cases:0.00%
controls:0.29%
cases:0.00%
controls:0.46%
0
5
172
1715
0
6
172
1714
—
—
—
0
5
167
1690
0
7
145
1515
Functional dyspepsia
K30 [45591584]
K30 [45591584]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
0
12
145
1510
Central perforation of tympanic membrane
H72.0 [45538342]
H72.0 [45538342]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
172
1715
—
—
—
—
—
—
X-ray examination of the lungs in one projection
GD1PA [2001303645]
GD1PA [2001303645]
1.9e+00
—
—
—
—
—
1.2e+00
cases:2.91%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
cases:4.14%
controls:1.25%
5
8
167
1712
—
—
—
—
—
6
19
139
1503
bicalutamide; oral
L02BB03 [21603837]
L02BB03 [21603837]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
5
145
1517
Amphetamines [Presence] in Urine
3349-8 [3027944]
3349-8 [3027944]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
0
9
145
1513
azelaic acid; ointment
D10AX03 [21602314]
D10AX03 [21602314]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
5
145
1517
tamsulosin; oral
G04CA02 [21602669]
G04CA02 [21602669]
-8.6e-02
—
—
—
—
5.1e-02
3.5e-01
cases:4.07%
controls:4.42%
—
—
—
—
—
—
—
—
cases:3.59%
controls:3.42%
cases:7.59%
controls:5.45%
7
76
165
1644
—
—
—
—
6
58
161
1637
11
83
134
1439
SMOKING - SMOKE2: no - SMOKE3: Unspecified - SMOKE5: Unspecified
SMOKING-2-0-0 [2002330112]
SMOKING-2-0-0 [2002330112]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
172
1712
—
—
—
—
—
—
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
1751-7 [3024561]
4.3e-02
4.1e-01
—
—
—
8.3e-01
-5.9e-02
cases:5.81%
controls:5.58%
cases:5.23%
controls:3.55%
—
—
—
—
—
—
cases:8.38%
controls:3.83%
cases:8.28%
controls:8.74%
10
96
162
1624
9
61
163
1659
—
—
—
14
65
153
1630
12
133
133
1389
metformin; oral
A10BA02 [21600747]
A10BA02 [21600747]
-5.0e-01
-3.2e-01
—
—
—
8.5e-02
2.4e-01
cases:4.65%
controls:7.44%
cases:5.23%
controls:7.09%
—
—
—
—
—
—
cases:7.78%
controls:7.20%
cases:12.41%
controls:9.99%
8
128
164
1592
9
122
163
1598
—
—
—
13
122
154
1573
18
152
127
1370
Tympanometry
SPAT1044 [2001700145]
SPAT1044 [2001700145]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
6
145
1516
Upper respiratory infection acute
R74 [2002000942]
R74 [2002000942]
—
-1.0e+50
—
—
—
—
3.3e-01
—
—
cases:0.00%
controls:1.05%
—
—
—
—
—
—
—
—
cases:6.90%
controls:5.06%
—
0
18
172
1702
—
—
—
—
10
77
135
1445
Single live birth
Z37.0 [45571346]
Z37.0 [45571346]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
172
1710
—
—
—
—
—
—
Disorder of lipoprotein metabolism, unspecified
E78.9 [45581384]
E78.9 [45581384]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
172
1713
—
—
—
—
—
—
Vacuum extractor delivery
O81.4 [45582577]
O81.4 [45582577]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
172
1715
—
—
—
—
—
—
chondroitin sulfate
M01AX25 [21604013]
M01AX25 [21604013]
—
—
—
—
—
-1.0e+50
8.7e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
cases:4.14%
controls:1.77%
—
—
—
—
—
0
9
167
1686
6
27
139
1495
Dental X-ray, bite-wing X-ray on one side of the mouth
EB1SA [2001301918]
EB1SA [2001301918]
-6.8e-01
—
—
—
—
1.5e-01
-5.5e-01
cases:4.07%
controls:7.73%
—
—
—
—
—
—
—
—
cases:2.99%
controls:2.60%
cases:6.21%
controls:10.25%
7
133
165
1587
—
—
—
—
5
44
162
1651
9
156
136
1366
General and Unspecified, Clarification/discussion RFE/demand
A48 [2002000182]
A48 [2002000182]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
0
7
167
1688
—
Other specified diseases of hard tissues of teeth
K03.88 [2000502701]
K03.88 [2000502701]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
5
145
1517
Hepatitis C virus Ab [Presence] in Serum
16128-1 [3017143]
16128-1 [3017143]
—
—
—
—
—
—
5.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.45%
controls:2.10%
—
—
—
—
—
—
5
32
140
1490
SMOKING - SMOKE2: no - SMOKE3: former - SMOKE5: Unspecified
SMOKING-2-2-0 [2002330110]
SMOKING-2-2-0 [2002330110]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
0
11
172
1709
—
—
—
—
—
Adjustment and management of cardiac devices
Z45.0 [45595515]
Z45.0 [45595515]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
0
5
172
1715
—
—
—
—
0
5
167
1690
—
Counselling and guidance which enhance independent living
R2130 [2001310196]
R2130 [2001310196]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.16%
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.12%
0
20
172
1700
0
7
172
1713
—
—
—
—
0
17
145
1505
Assessment of need for oral health care, extensive
SAD02 [2001310288]
SAD02 [2001310288]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
0
5
172
1715
—
—
—
—
—
0
7
145
1515
dapagliflozin; oral
A10BK01 [1123890]
A10BK01 [1123890]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.41%
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
0
7
172
1713
0
8
172
1712
—
—
—
—
—
gabapentin; oral
N02BF01 [955005]
N02BF01 [955005]
1.1e+00
1.3e+00
—
—
—
1.1e+00
8.7e-01
cases:4.07%
controls:1.45%
cases:2.91%
controls:0.81%
—
—
—
—
—
—
cases:2.99%
controls:1.00%
cases:6.90%
controls:3.02%
7
25
165
1695
5
14
167
1706
—
—
—
5
17
162
1678
10
46
135
1476
Neck artery ultrasound examination with Doppler method
PA6DE [2001308705]
PA6DE [2001308705]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
172
1712
—
—
—
—
—
—
Endomysium IgA Ab [Titer] in Serum
10863-9 [3020961]
10863-9 [3020961]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
172
1715
—
—
—
—
—
—
Presbycusis
H91.1 [45591444]
H91.1 [45591444]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
0
9
172
1711
—
—
—
—
—
0
8
145
1514
Own respiration
WX720 [2001310823]
WX720 [2001310823]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
5
145
1517
SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
94500-6 [706163]
94500-6 [706163]
1.0e-01
-2.1e-01
—
—
—
2.3e-01
-1.8e-01
cases:5.81%
controls:5.29%
cases:2.91%
controls:3.55%
—
—
—
—
—
—
cases:4.79%
controls:3.83%
cases:8.28%
controls:9.72%
10
91
162
1629
5
61
167
1659
—
—
—
8
65
159
1630
12
148
133
1374
PEEP
WX722 [2001310825]
WX722 [2001310825]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
172
1714
—
—
—
—
—
—
sertraline; oral
N06AB06 [21604714]
N06AB06 [21604714]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
0
14
172
1706
—
—
—
0
10
167
1685
—
Atherosclerotic heart disease
I25.1 [45596196]
I25.1 [45596196]
-2.4e-01
—
-1.0e+50
—
—
—
3.3e-01
cases:2.91%
controls:3.66%
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
cases:6.90%
controls:5.06%
5
63
167
1657
—
0
6
172
1714
—
—
—
10
77
135
1445
Laparoscopic cholecystectomy
JKA21 [2001305294]
JKA21 [2001305294]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.10%
—
—
—
—
—
—
—
—
—
—
—
—
0
19
172
1701
—
—
—
—
—
—
insulin lispro; parenteral
A10AB04 [21600718]
A10AB04 [21600718]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
0
10
171
1708
—
—
Non-insulin dependent diabetes diabetic hypoglycaemic coma
E11.00 [2000501437]
E11.00 [2000501437]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
172
1715
—
—
—
—
—
—
Bilirubin.conjugated [Moles/volume] in Serum or Plasma
29760-6 [3005772]
29760-6 [3005772]
—
—
—
—
—
1.9e+00
5.8e-01
—
—
—
—
—
—
—
—
—
—
cases:2.99%
controls:0.47%
cases:4.14%
controls:2.37%
—
—
—
—
—
5
8
162
1687
6
36
139
1486
Diaphragmatic hernia without obstruction or gangrene
K44.9 [45533596]
K44.9 [45533596]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
0
10
145
1512
glimepiride; oral
A10BB12 [21600761]
A10BB12 [21600761]
-1.0e+50
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:1.57%
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
0
27
172
1693
—
—
—
0
5
171
1713
—
—
Volume in Urine collected for unspecified duration
19153-6 [3004775]
19153-6 [3004775]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
7
145
1515
Alzheimer disease
G30 [45538101]
G30 [45538101]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
0
6
172
1714
—
—
—
—
—
0
6
145
1516
Presence of orthopaedic joint implants
Z96.6 [45600385]
Z96.6 [45600385]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
0
5
172
1715
—
—
—
—
—
0
6
145
1516
Bacteria [Presence] in Urine
87829-8 [36304419]
87829-8 [36304419]
-2.7e-01
—
—
—
—
5.1e-01
9.3e-01
cases:2.91%
controls:3.78%
—
—
—
—
—
—
—
—
cases:3.59%
controls:2.18%
cases:11.03%
controls:4.66%
5
65
167
1655
—
—
—
—
6
37
161
1658
16
71
129
1451
pseudoephedrine, combinations; oral
R01BA52 [21603213]
R01BA52 [21603213]
3.4e-01
—
-1.0e+50
—
-1.0e+50
1.9e-01
8.3e-03
cases:9.30%
controls:6.80%
—
—
cases:0.00%
controls:0.29%
—
—
cases:0.00%
controls:0.29%
cases:2.99%
controls:2.48%
cases:8.28%
controls:8.21%
16
117
156
1603
—
0
5
172
1715
—
0
5
171
1713
5
42
162
1653
12
125
133
1397
Hemoglobin [Presence] in Urine by Test strip
5794-3 [3011397]
5794-3 [3011397]
4.6e-01
—
—
—
—
—
1.2e-02
cases:4.07%
controls:2.62%
—
—
—
—
—
—
—
—
—
—
cases:5.52%
controls:5.45%
7
45
165
1675
—
—
—
—
—
8
83
137
1439
Fracture of lower end of radius
S52.5 [45573842]
S52.5 [45573842]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
—
—
0
17
172
1703
—
—
—
—
—
—
Peak expiratory flow measurement
SPAT1057 [2001700158]
SPAT1057 [2001700158]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
5
145
1517
Recording of ECG
SPAT1097 [2001700198]
SPAT1097 [2001700198]
—
—
—
—
—
—
7.6e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.45%
controls:1.64%
—
—
—
—
—
—
5
25
140
1497
Primary gonarthrosis, bilateral
M17.0 [45562648]
M17.0 [45562648]
—
—
—
—
—
—
1.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.52%
controls:2.04%
—
—
—
—
—
—
8
31
137
1491
Percutaneous transluminal coronary angioplasty (PTCA), balloon only
FN2AA [2001303088]
FN2AA [2001303088]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
5
145
1517
Pregnancy confirmed
Z32.1 [45566418]
Z32.1 [45566418]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
0
7
172
1713
—
—
—
—
—
0
6
145
1516
solifenacin; oral
G04BD08 [21602641]
G04BD08 [21602641]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
172
1708
—
—
—
—
—
—
Dorsalgia
M54 [45553203]
M54 [45553203]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.40%
—
—
—
—
—
—
—
—
—
—
—
—
0
24
172
1696
—
—
—
—
—
—
Treatment of a patient needing special arrangements
WYA30 [2001310874]
WYA30 [2001310874]
1.6e+00
—
—
—
—
—
—
cases:3.49%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
6
13
166
1707
—
—
—
—
—
—
Routine postpartum follow-up
Z39.2 [45547306]
Z39.2 [45547306]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.87%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
cases:0.00%
controls:0.79%
0
15
172
1705
—
—
—
—
0
6
167
1689
0
12
145
1510
clarithromycin; oral, parenteral
J01FA09 [21602977]
J01FA09 [21602977]
6.1e-01
—
—
—
—
-1.0e+50
5.8e-01
cases:5.81%
controls:3.26%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.88%
cases:4.14%
controls:2.37%
10
56
162
1664
—
—
—
—
0
15
167
1680
6
36
139
1486
glucosamine; oral
M01AX05 [21604002]
M01AX05 [21604002]
6.1e-01
—
—
—
-1.0e+50
—
—
cases:5.81%
controls:3.26%
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
10
56
162
1664
—
—
—
0
5
171
1713
—
—
Sedation and analgesia
WX002 [2001310758]
WX002 [2001310758]
1.1e+00
—
—
—
—
—
1.2e+00
cases:5.81%
controls:1.98%
—
—
—
—
—
—
—
—
—
—
cases:5.52%
controls:1.71%
10
34
162
1686
—
—
—
—
—
8
26
137
1496
Chronic obstructive pulmonary disease with acute lower respiratory infection
J44.0 [45601131]
J44.0 [45601131]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
172
1713
—
—
—
—
—
—
furosemide and potassium-sparing agents
C03EB01 [21601554]
C03EB01 [21601554]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
172
1711
—
—
—
—
—
—
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
51483-6 [3030467]
-1.3e-01
—
—
—
—
5.7e-01
7.9e-01
cases:3.49%
controls:3.95%
—
—
—
—
—
—
—
—
cases:4.19%
controls:2.42%
cases:10.34%
controls:4.99%
6
68
166
1652
—
—
—
—
7
41
160
1654
15
76
130
1446
Carcinoembryonic Ag [Mass/volume] in Serum or Plasma
2039-6 [3003785]
2039-6 [3003785]
—
—
—
—
—
—
9.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.14%
controls:1.71%
—
—
—
—
—
—
6
26
139
1496
Examination of ears and hearing
Z01.1 [45547279]
Z01.1 [45547279]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
0
9
167
1686
—
Postmenopausal bleeding
N95.0 [45567872]
N95.0 [45567872]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
7
145
1515
Borrelia burgdorferi IgG Ab [Units/volume] in Serum
7817-0 [3016888]
7817-0 [3016888]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
0
5
172
1715
—
—
—
—
—
atenolol; oral, parenteral
C07AB03 [21601685]
C07AB03 [21601685]
—
-1.0e+50
—
—
-1.0e+50
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.76%
—
—
—
—
cases:0.00%
controls:0.35%
cases:0.00%
controls:0.77%
cases:0.00%
controls:0.79%
—
0
13
172
1707
—
—
0
6
171
1712
0
13
167
1682
0
12
145
1510
Nausea
D09 [2002000308]
D09 [2002000308]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
6
145
1516
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
5802-4 [3021601]
2.8e-01
4.4e-01
—
—
—
4.8e-01
1.9e-01
cases:7.56%
controls:5.81%
cases:5.23%
controls:3.43%
—
—
—
—
—
—
cases:6.59%
controls:4.19%
cases:13.79%
controls:11.70%
13
100
159
1620
9
59
163
1661
—
—
—
11
71
156
1624
20
178
125
1344
Skin, Repair/fix-suture/cast/prosth device
S54 [2002001018]
S54 [2002001018]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
0
8
145
1514
Other visual field testing
CS494 [2001301478]
CS494 [2001301478]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
0
5
172
1715
—
—
—
—
—
nystatin
D01AA01 [21601911]
D01AA01 [21601911]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
172
1713
—
—
—
—
—
—
Limited function/disability (L)
L28 [2002000647]
L28 [2002000647]
1.1e+00
—
—
—
—
—
1.2e+00
cases:3.49%
controls:1.16%
—
—
—
—
—
—
—
—
—
—
cases:7.59%
controls:2.50%
6
20
166
1700
—
—
—
—
—
11
38
134
1484
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
R29.8 [45587505]
R29.8 [45587505]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
0
9
172
1711
—
—
—
—
—
0
9
145
1513
rivaroxaban; oral
B01AF01 [43534761]
B01AF01 [43534761]
—
—
—
—
-1.0e+50
—
8.0e-01
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
cases:4.14%
controls:1.91%
—
—
—
—
0
8
171
1710
—
6
29
139
1493
Operation for humeroscapular osteochondritis, arthroscopic
NBF25 [2001307294]
NBF25 [2001307294]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
5
145
1517
Puncture of vitreous body with injection of medication
CKD05 [2001301407]
CKD05 [2001301407]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.47%
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
0
8
172
1712
0
6
172
1714
—
—
—
—
—
Haptoglobin [Mass/volume] in Serum or Plasma
4542-7 [3012336]
4542-7 [3012336]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
0
5
172
1715
—
—
—
—
—
Ankylosing spondylitis
M45 [45591841]
M45 [45591841]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.29%
cases:0.00%
controls:0.29%
—
—
—
—
—
—
cases:0.00%
controls:0.35%
cases:0.00%
controls:0.59%
0
5
172
1715
0
5
172
1715
—
—
—
0
6
167
1689
0
9
145
1513
General and Unspecified, Medication/prescr/renewal
A50 [2002000184]
A50 [2002000184]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
0
5
172
1715
—
—
—
—
0
5
167
1690
—
Other physical therapy
Z50.1 [45600331]
Z50.1 [45600331]
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:2.99%
controls:0.00%
—
—
—
—
—
—
—
5
0
162
1695
—
telmisartan and diuretics
C09DA07 [21601839]
C09DA07 [21601839]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
0
11
167
1684
—
Coxarthrosis [arthrosis of hip]
M16 [45577162]
M16 [45577162]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
6
145
1516
Pain in joint
M25.5 [45586941]
M25.5 [45586941]
—
—
—
—
—
—
2.9e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.52%
controls:4.20%
—
—
—
—
—
—
8
64
137
1458
hydrocortisone and antiinfectives
S03CA04 [21605208]
S03CA04 [21605208]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
0
11
172
1709
—
—
—
0
6
167
1689
—
Protein [Mass/volume] in Cerebral spinal fluid
2880-3 [3019473]
2880-3 [3019473]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
172
1714
—
—
—
—
—
—
Emergency visit or other similar visit involving procedures
WYA05 [2001310871]
WYA05 [2001310871]
-3.5e-02
—
—
—
—
5.7e-01
2.6e-01
cases:6.98%
controls:7.21%
—
—
—
—
—
—
—
—
cases:4.79%
controls:2.77%
cases:11.72%
controls:9.26%
12
124
160
1596
—
—
—
—
8
47
159
1648
17
141
128
1381
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
51480-2 [3031040]
-1.9e-02
6.1e-01
—
—
—
3.2e-01
4.9e-01
cases:9.88%
controls:10.06%
cases:8.72%
controls:4.94%
—
—
—
—
—
—
cases:7.78%
controls:5.78%
cases:19.31%
controls:12.75%
17
173
155
1547
15
85
157
1635
—
—
—
13
98
154
1597
28
194
117
1328
Other obesity
E66.8 [45533036]
E66.8 [45533036]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
0
6
172
1714
—
—
—
—
—
Clinical Cytogenetics and Genomics
OMOP4822000 [32411]
OMOP4822000 [32411]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
172
1709
—
—
—
—
—
—
Generalized anxiety disorder
F41.1 [45571764]
F41.1 [45571764]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
0
5
167
1690
—
Anxiety disorder, unspecified
F41.9 [45542849]
F41.9 [45542849]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.25%
—
0
6
172
1714
—
—
—
—
0
19
145
1503
orphenadrine, combinations
M03BC51 [21604113]
M03BC51 [21604113]
5.7e-01
—
—
—
—
—
—
cases:5.23%
controls:3.02%
—
—
—
—
—
—
—
—
—
—
—
—
9
52
163
1668
—
—
—
—
—
—
Unstable angina
I20.01 [2000502385]
I20.01 [2000502385]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
172
1712
—
—
—
—
—
—
Bell palsy
G51.0 [45571815]
G51.0 [45571815]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
6
145
1516
Supervision of normal first pregnancy
Z34.0 [45595500]
Z34.0 [45595500]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.52%
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
0
9
172
1711
0
5
172
1715
—
—
—
—
0
8
145
1514
Other blockage of nerve
WX290 [2001310792]
WX290 [2001310792]
-8.4e-02
2.5e-01
—
—
-1.0e+50
7.0e-01
3.1e-01
cases:6.40%
controls:6.92%
cases:2.91%
controls:2.27%
—
—
—
—
cases:0.00%
controls:0.41%
cases:4.19%
controls:2.12%
cases:13.10%
controls:9.92%
11
119
161
1601
5
39
167
1681
—
—
0
7
171
1711
7
36
160
1659
19
151
126
1371
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
28540-3 [3003338]
-1.3e-01
-1.5e-01
9.3e-01
—
6.7e-01
-2.0e-01
-3.0e-01
cases:15.70%
controls:17.44%
cases:12.21%
controls:13.90%
cases:6.40%
controls:2.62%
—
—
cases:8.19%
controls:4.37%
cases:11.98%
controls:14.22%
cases:23.45%
controls:29.24%
27
300
145
1420
21
239
151
1481
11
45
161
1675
—
14
75
157
1643
20
241
147
1454
34
445
111
1077
Creatinine [Moles/volume] in Urine
14683-7 [3009508]
14683-7 [3009508]
-2.3e-01
3.7e-01
—
—
—
4.1e-01
-3.4e-02
cases:3.49%
controls:4.36%
cases:3.49%
controls:2.44%
—
—
—
—
—
—
cases:5.39%
controls:3.66%
cases:8.28%
controls:8.54%
6
75
166
1645
6
42
166
1678
—
—
—
9
62
158
1633
12
130
133
1392
ENMG
XA402 [2001300405]
XA402 [2001300405]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
7
145
1515
Albumin [Mass/time] in Urine collected for unspecified duration
49002-9 [3050449]
49002-9 [3050449]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
cases:0.00%
controls:1.05%
—
—
—
—
—
0
6
167
1689
0
16
145
1506
Consultation of another employee
SPAT1260 [2001700361]
SPAT1260 [2001700361]
1.2e+00
—
—
—
—
—
9.2e-01
cases:4.65%
controls:1.45%
—
—
—
—
—
—
—
—
—
—
cases:4.83%
controls:1.97%
8
25
164
1695
—
—
—
—
—
7
30
138
1492
Personal history of diseases of the digestive system
Z87.1 [45542474]
Z87.1 [45542474]
-1.0e-01
4.3e-01
—
—
-1.0e+50
5.2e-01
3.1e-01
cases:5.81%
controls:6.40%
cases:4.07%
controls:2.67%
—
—
—
—
cases:0.00%
controls:0.47%
cases:4.19%
controls:2.54%
cases:10.34%
controls:7.82%
10
110
162
1610
7
46
165
1674
—
—
0
8
171
1710
7
43
160
1652
15
119
130
1403
desonide
D07AB08 [21602112]
D07AB08 [21602112]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
0
8
172
1712
—
—
—
0
8
167
1687
—
Visual field testing with Humphrey automated perimetry
CS434 [2001301476]
CS434 [2001301476]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
0
6
172
1714
—
—
—
—
0
5
145
1517
Obstetrics / Gynecology
16 [38004461]
16 [38004461]
-1.1e-01
-1.7e-01
—
—
-1.0e+50
—
1.6e-01
cases:9.30%
controls:10.23%
cases:2.91%
controls:3.43%
—
—
—
—
cases:0.00%
controls:0.64%
—
—
cases:9.66%
controls:8.34%
16
176
156
1544
5
59
167
1661
—
—
0
11
171
1707
—
14
127
131
1395
Cerebral infarction due to embolism of cerebral arteries
I63.4 [45591475]
I63.4 [45591475]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
172
1715
—
—
—
—
—
—
Burn-out
Z73.0 [45576177]
Z73.0 [45576177]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
5
145
1517
Scabies
B86 [45561769]
B86 [45561769]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
6
145
1516
Other extensive ultrasound examination of artery
PG1DE [2001309713]
PG1DE [2001309713]
—
1.0e+50
—
—
—
—
—
—
—
cases:2.91%
controls:0.00%
—
—
—
—
—
—
—
—
—
—
—
5
0
167
1720
—
—
—
—
—
Other and unspecified symptoms and signs involving cognitive functions and awareness
R41.8 [45534452]
R41.8 [45534452]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
0
6
172
1714
—
—
—
0
7
167
1688
—
Chronic apical periodontitis
K04.5 [45586691]
K04.5 [45586691]
-1.5e-01
—
—
—
—
—
8.4e-01
cases:2.91%
controls:3.37%
—
—
—
—
—
—
—
—
—
—
cases:6.90%
controls:3.09%
5
58
167
1662
—
—
—
—
—
10
47
135
1475
Other specified counselling
Z71.8 [45581061]
Z71.8 [45581061]
9.0e-01
1.2e+00
—
—
—
1.3e+00
5.1e-01
cases:6.98%
controls:2.97%
cases:4.07%
controls:1.28%
—
—
—
—
—
—
cases:5.99%
controls:1.71%
cases:8.97%
controls:5.58%
12
51
160
1669
7
22
165
1698
—
—
—
10
29
157
1666
13
85
132
1437
betamethasone
A07EA04 [21600656]
A07EA04 [21600656]
2.1e-02
—
-1.0e+50
—
—
—
-3.9e-01
cases:5.81%
controls:5.70%
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
cases:4.83%
controls:6.96%
10
98
162
1622
—
0
8
172
1712
—
—
—
7
106
138
1416
dexamethasone; local oral
A01AC02 [21600035]
A01AC02 [21600035]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
0
6
172
1714
—
—
—
—
—
Postpartum check-up
SPAT1380 [2001700480]
SPAT1380 [2001700480]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
172
1713
—
—
—
—
—
—
adalimumab; parenteral
L04AB04 [21603911]
L04AB04 [21603911]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
5
145
1517
Lumbar and other intervertebral disc disorders with radiculopathy
M51.1 [45562747]
M51.1 [45562747]
—
-1.0e+50
—
—
—
-1.0e+50
5.1e-01
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
cases:0.00%
controls:0.71%
cases:3.45%
controls:2.10%
—
0
10
172
1710
—
—
—
0
12
167
1683
5
32
140
1490
Sentinel node biopsy
PJA12 [2001309627]
PJA12 [2001309627]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
172
1713
—
—
—
—
—
—
diclofenac
D11AX18 [21602355]
D11AX18 [21602355]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
0
8
167
1687
—
mianserin; oral
N06AX03 [21604732]
N06AX03 [21604732]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
0
5
167
1690
—
fusidic acid
S01AA13 [21603564]
S01AA13 [21603564]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
0
9
167
1686
—
Abdominal pain epigastric
D02 [2002000301]
D02 [2002000301]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
7
145
1515
Hepatitis A virus Ab [Presence] in Serum
20575-7 [3016650]
20575-7 [3016650]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
0
5
172
1715
—
—
—
—
—
0
5
145
1517
mupirocin; nasal
R01AX06 [21603201]
R01AX06 [21603201]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
172
1711
—
—
—
—
—
—
Limited function/disability NOS
A28 [2002000162]
A28 [2002000162]
—
—
-1.0e+50
—
—
1.0e+00
5.0e-01
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
cases:2.99%
controls:1.12%
cases:5.52%
controls:3.42%
—
—
0
6
172
1714
—
—
5
19
162
1676
8
52
137
1470
Thrombophilia screening test
314089003 [4195642]
314089003 [4195642]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
172
1714
—
—
—
—
—
—
codeine and ibuprofen
N02AJ08 [1123631]
N02AJ08 [1123631]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
172
1714
—
—
—
—
—
—
Localized swelling, mass and lump, unspecified
R22.9 [45577788]
R22.9 [45577788]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
172
1710
—
—
—
—
—
—
ispaghula (psylla seeds); oral
A06AC01 [21600555]
A06AC01 [21600555]
8.6e-02
—
—
—
-1.0e+50
1.2e+00
7.3e-01
cases:2.91%
controls:2.67%
—
—
—
—
—
—
cases:0.00%
controls:0.29%
cases:4.19%
controls:1.30%
cases:6.21%
controls:3.09%
5
46
167
1674
—
—
—
0
5
171
1713
7
22
160
1673
9
47
136
1475
Multiple sclerosis
G35 [45571794]
G35 [45571794]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
172
1715
—
—
—
—
—
—
clopidogrel; oral
B01AC04 [21600989]
B01AC04 [21600989]
6.2e-01
—
—
—
-1.0e+50
—
6.4e-01
cases:4.65%
controls:2.56%
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
cases:4.14%
controls:2.23%
8
44
164
1676
—
—
—
0
7
171
1711
—
6
34
139
1488
Periodontal treatment, brief
SDA02 [2001310327]
SDA02 [2001310327]
—
—
—
—
—
—
-6.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.45%
controls:6.31%
—
—
—
—
—
—
5
96
140
1426
linagliptin; oral
A10BH05 [40251691]
A10BH05 [40251691]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
0
6
172
1714
—
—
—
0
8
167
1687
—
Fracture of neck of femur
S72.0 [45593656]
S72.0 [45593656]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
cases:0.00%
controls:0.46%
—
—
—
—
—
0
5
167
1690
0
7
145
1515
Injury of other blood vessels at lower leg level
S85.8 [45545864]
S85.8 [45545864]
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
cases:9.30%
controls:0.00%
—
—
—
—
—
—
—
—
—
16
0
156
1720
—
—
—
chlorhexidine
D09AA12 [21602275]
D09AA12 [21602275]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
0
12
167
1683
—
Chloride [Moles/volume] in Venous blood
41649-5 [3035285]
41649-5 [3035285]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
6
145
1516
acetazolamide; oral, parenteral
S01EC01 [21603693]
S01EC01 [21603693]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
172
1715
—
—
—
—
—
—
Elevated blood pressure
K85 [2002000612]
K85 [2002000612]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.64%
—
—
—
—
—
—
0
25
145
1497
Demanding ultrsound examination of uterus, parametrium and lower part of abdomen with speciel methods
LC2DE [2001306545]
LC2DE [2001306545]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
172
1715
—
—
—
—
—
—
Initiation, adjustment, discontinuation or repetition of medication
SPAT1253 [2001700354]
SPAT1253 [2001700354]
4.6e-01
—
—
—
—
1.1e+00
9.4e-01
cases:5.23%
controls:3.37%
—
—
—
—
—
—
—
—
cases:4.79%
controls:1.59%
cases:11.03%
controls:4.60%
9
58
163
1662
—
—
—
—
8
27
159
1668
16
70
129
1452
Other gastroenteritis and colitis of infectious and unspecified origin
A09 [45605189]
A09 [45605189]
—
—
—
—
—
—
1.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.52%
controls:2.10%
—
—
—
—
—
—
8
32
137
1490
General health counselling
SPAT1312 [2001700413]
SPAT1312 [2001700413]
1.7e-01
—
—
—
—
—
6.3e-01
cases:4.65%
controls:3.95%
—
—
—
—
—
—
—
—
—
—
cases:6.90%
controls:3.81%
8
68
164
1652
—
—
—
—
—
10
58
135
1464
Complicated extraction of tooth
EBA05 [2001301924]
EBA05 [2001301924]
8.7e-01
-1.0e+50
—
—
—
—
6.1e-01
cases:4.07%
controls:1.74%
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
cases:4.83%
controls:2.69%
7
30
165
1690
0
10
172
1710
—
—
—
—
7
41
138
1481
Other otitis externa
H60.8 [45567109]
H60.8 [45567109]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
172
1714
—
—
—
—
—
—
LabWAS
↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
17
40
4.60
6.92
3.7
2.4
0.37
0.34
iu/ml
0.15
12
21
60
331
2.24
5.64
3.3
2.5
—
—
—
0
0
27
103
2.92
5.46
2.1
1.5
—
—
—
0
0
96
650
2.07
5.21
4.7
2.8
—
—
estimate
—
0
0
117
872
2.06
4.66
7.8
4.7
6.68
6.68
mmol/l
0.01
111
818
55
324
2.02
4.20
2.0
1.7
1.35
1.55
mg/l
0.25
48
259
26
112
2.56
4.17
12.4
4.3
1.21
1.22
mmol/l
0.56
26
95
89
626
1.87
3.96
4.2
3.6
33.67
48.66
ng/l
0.72
63
436
8
11
7.56
3.90
1.0
1.1
—
—
—
0
0
14
40
3.72
3.70
3.0
1.4
—
—
—
0
0
40
220
2.06
3.64
2.5
2.0
31.58
29.29
s
1.55
40
213
68
455
1.81
3.44
4.2
3.2
2110.73
1241.06
ng/l
0.94
60
383
72
491
1.80
3.41
3.0
2.5
50.55
63.16
u/l
0.76
65
462
44
258
1.95
3.33
2.6
1.9
—
—
—
0
0
6
7
8.82
3.29
2.3
2.1
—
—
—
0
0
28
140
2.19
3.23
6.1
3.4
—
—
—
0
0
8
15
5.53
3.23
1.0
1.1
—
—
—
0
0
94
702
1.74
3.20
14.8
7.6
1.20
1.21
mmol/l
0.52
79
606
12
35
3.61
3.18
1.1
1.2
—
—
—
0
0
13
45
3.04
3.10
2.1
1.6
—
—
—
0
0
17
69
2.62
3.07
1.4
1.5
—
—
—
0
0
12
37
3.41
3.00
2.2
1.4
—
—
—
0
0
6
9
6.86
2.89
1.0
1.0
—
—
—
0
0
158
1405
2.44
2.87
25.4
15.4
78.90
82.31
ml/min/173m2
1.00
149
1306
11
33
3.49
2.87
2.3
1.5
—
—
—
0
0
35
200
1.94
2.84
2.6
1.7
—
—
—
0
0
31
171
1.99
2.77
12.2
7.1
12.28
12.12
kpa
0.04
31
165
31
171
1.99
2.77
12.2
7.1
5.31
5.01
kpa
1.02
31
163
43
265
1.83
2.77
5.7
3.1
0.83
0.82
mmol/l
0.14
43
253
7
14
5.16
2.75
1.0
1.1
—
—
—
0
0
10
29
3.59
2.74
2.4
1.4
—
—
—
0
0
12
44
2.86
2.60
2.2
1.6
—
—
—
0
0
12
44
2.86
2.60
1.5
1.3
—
—
—
0
0
26
138
2.04
2.58
20.0
8.3
13.48
9.68
mmol/l
1.36
26
131
33
192
1.89
2.53
2.8
1.8
—
—
—
0
0
8
21
3.94
2.49
1.8
1.2
—
—
—
0
0
30
170
1.93
2.49
5.4
4.7
273.20
250.96
u/l
0.43
30
163
10
32
3.25
2.48
2.4
1.4
—
—
—
0
0
88
677
1.61
2.46
5.7
2.9
273.41
130.15
ug/l
0.65
82
634
6
12
5.14
2.42
2.0
1.2
—
—
—
0
0
71
520
1.62
2.41
5.0
3.4
—
—
—
0
0
11
39
2.94
2.39
3.1
3.1
—
—
—
0
0
5
8
6.39
2.38
2.2
1.1
—
—
—
0
0
9
28
3.33
2.34
1.8
1.3
—
—
—
0
0
9
28
3.33
2.34
1.8
1.3
—
—
—
0
0
12
47
2.67
2.32
2.5
3.5
1.97
1.54
mg/l
0.62
12
41
9
29
3.22
2.26
1.8
1.6
—
—
—
0
0
11
42
2.73
2.19
1.8
1.2
—
—
—
0
0
7
19
3.79
2.17
2.0
1.2
—
—
—
0
0
42
276
1.69
2.15
4.8
3.4
567.86
382.79
ng/l
0.15
36
209
44
295
1.66
2.09
1.7
1.7
489.08
46063434.01
pmol/l
0.50
37
254
105
864
1.55
2.05
12.7
10.2
4.71
4.05
e9/l
1.33
95
753
22
120
1.95
2.04
2.1
2.9
65.98
67.08
g/l
0.32
22
114
8
26
3.17
2.04
3.5
1.8
11.00
11.15
mmol/l
—
8
26
19
99
2.03
1.99
11.4
8.2
24.40
24.47
mmol/l
0.02
19
99
64
483
1.52
1.82
3.5
3.5
2.32
2.36
mmol/l
1.59
59
441
8
29
2.84
1.81
10.1
3.6
20.07
11.89
pmol/l
—
8
29
8
29
2.84
1.81
2.1
1.5
—
—
—
0
0
77
605
1.49
1.80
3.1
2.5
75.70
74.41
nmol/l
0.13
70
539
55
403
1.53
1.78
4.8
3.3
0.89
0.34
e6/l
0.32
45
294
36
240
1.63
1.73
2.1
1.6
1436.33
1136.66
nmol/l
0.74
30
180
8
31
2.66
1.68
1.5
1.3
7035.88
7405.91
e6/l
—
8
23
11
49
2.33
1.67
1.4
2.0
—
—
—
0
0
94
782
1.44
1.58
5.2
3.7
0.00
0.00
estimate
-0.00
31
170
95
794
1.44
1.54
5.3
3.8
0.00
0.02
estimate
0.50
29
162
10
45
2.30
1.49
1.8
1.6
0.00
0.00
g/l
—
10
45
94
791
1.41
1.43
5.3
3.7
0.00
0.00
estimate
-0.00
31
172
11
53
2.15
1.42
1.5
2.2
—
—
—
0
0
62
487
1.43
1.38
3.8
4.0
22.47
9.00
mg/mmol
0.60
42
316
145
1330
1.56
1.33
5.1
4.8
1.84
1.96
mu/l
0.79
133
1224
57
445
1.42
1.31
5.4
3.6
0.00
0.02
estimate
0.74
23
154
8
35
2.35
1.28
1.0
1.1
—
—
—
0
0
150
1390
1.60
1.27
6.4
6.3
38.91
39.28
mmol/mol
0.24
143
1309
156
1462
1.68
1.22
30.5
15.5
25.86
25.15
mg/l
0.11
144
1204
74
611
1.37
1.21
5.7
3.6
0.00
0.04
estimate
0.80
25
146
21
136
1.62
1.15
4.9
2.9
5.48
4.35
kpa
1.26
21
129
14
81
1.79
1.13
2.9
3.3
3.97
4.49
pmol/l
1.76
14
71
18
114
1.65
1.07
2.7
2.6
51.83
65.36
ml/min/173m2
—
6
45
9
46
2.01
1.05
1.1
1.2
—
—
—
0
0
5
22
2.31
1.04
3.0
1.2
—
—
—
0
0
5
23
2.21
0.98
1.0
1.1
—
—
—
0
0
9
50
1.84
0.98
4.9
4.5
66.88
69.50
mg/l
—
9
44
9
50
1.84
0.98
4.9
4.5
46.87
28.06
mg/l
—
9
44
7
36
1.98
0.98
1.0
1.6
—
—
—
0
0
55
446
1.34
0.98
4.7
3.3
0.00
0.02
estimate
1.08
24
136
23
159
1.52
0.97
7.1
3.9
5.79
5.61
kpa
0.37
23
153
6
27
2.26
0.94
1.2
1.3
—
—
—
0
0
14
86
1.68
0.94
1.6
1.9
—
—
—
0
0
51
422
1.30
0.78
2.1
1.7
21.38
20.42
nmol/l
0.16
46
353
5
25
2.03
0.73
2.2
1.3
—
—
—
0
0
9
58
1.58
0.71
1.7
1.4
—
—
—
0
0
71
622
1.24
0.67
2.6
2.1
94.57
95.11
pmol/l
0.04
38
324
34
273
1.31
0.65
3.4
2.7
2.42
2.45
mmol/l
0.95
29
245
5
29
1.75
0.64
2.8
1.3
—
188.00
—
0
5
13
88
1.52
0.62
3.6
3.3
1.12
1.42
mmol/l
—
8
63
148
1413
1.33
0.61
5.1
5.0
6.04
5.93
mmol/l
0.33
135
1306
31
248
1.30
0.61
3.6
2.9
1.18
0.92
e6/l
0.17
17
121
11
72
1.56
0.60
1.5
1.9
1.54
1.56
g/l
0.01
11
64
9
59
1.55
0.56
3.4
2.0
24.52
23.92
mmol/l
—
9
59
19
143
1.37
0.55
3.2
2.1
11.67
5.55
ug/l
0.40
19
123
41
345
1.25
0.55
1.3
1.3
0.71
1.64
u/ml
1.22
15
99
29
354
0.78
0.54
2.4
3.0
0.73
0.81
ug/l
0.24
18
211
19
144
1.36
0.53
2.7
2.6
0.19
0.21
g/l
0.55
19
135
100
926
1.19
0.50
3.5
3.0
—
—
—
0
0
7
45
1.58
0.49
1.0
1.1
—
5.31
—
0
7
11
76
1.48
0.49
1.5
2.3
—
—
—
0
0
7
46
1.54
0.49
1.1
1.2
—
—
—
0
0
26
210
1.28
0.48
1.8
2.2
1.27
1.54
%
1.23
20
184
5
85
0.58
0.46
1.2
1.0
—
—
—
0
0
7
49
1.45
0.46
1.0
1.3
—
2.38
—
0
9
116
1095
1.18
0.43
4.4
3.9
14.90
14.72
pmol/l
0.33
108
1001
41
469
0.84
0.42
3.6
4.2
23.88
22.08
%
0.31
18
224
12
88
1.39
0.41
4.5
2.4
0.62
0.60
%
0.07
12
88
0
19
0.00
0.39
0.0
1.4
—
0.96
—
0
11
0
19
0.00
0.39
0.0
1.4
—
1.01
—
0
11
0
19
0.00
0.39
0.0
1.4
—
1.23
—
0
11
9
67
1.36
0.39
1.6
2.2
—
—
—
0
0
6
41
1.48
0.36
1.5
1.4
—
—
—
0
0
31
267
1.20
0.34
1.2
1.3
18.01
31.61
iu/ml
—
10
78
136
1404
0.85
0.32
4.9
4.4
1.42
1.32
mmol/l
0.71
126
1292
17
138
1.26
0.32
2.1
2.0
—
—
—
0
0
30
261
1.18
0.30
2.0
1.5
—
—
—
0
0
5
74
0.67
0.26
1.6
1.2
0.88
0.92
g/l
—
5
74
27
237
1.16
0.25
3.9
3.0
1.09
1.80
e6/l
0.50
13
111
63
588
1.11
0.24
5.0
5.1
1.44
2.27
ug/l
1.48
54
530
5
39
1.29
0.23
1.4
1.2
—
—
—
0
0
5
40
1.26
0.22
1.4
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.4
—
148.88
—
0
11
0
10
0.00
0.21
0.0
1.1
—
11.20
—
0
10
0
13
0.00
0.21
0.0
2.5
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.0
—
—
—
0
0
0
14
0.00
0.20
0.0
3.4
—
—
—
0
0
18
156
1.17
0.19
2.1
2.0
—
—
—
0
0
144
1467
0.89
0.18
5.5
5.2
4.49
4.61
mmol/l
0.73
134
1370
5
66
0.75
0.17
2.4
3.3
16.60
1091.60
u/ml
—
5
56
26
235
1.13
0.17
1.3
1.3
1.22
11.26
u/ml
1.16
13
91
17
193
0.87
0.16
1.8
1.4
—
—
—
0
0
60
626
0.94
0.12
2.2
2.0
2.28
1.41
mmol/l
0.86
51
528
19
172
1.12
0.12
18.5
7.0
—
—
—
0
0
6
53
1.14
0.09
4.7
4.1
25.25
25.16
mmol/l
—
6
48
16
175
0.91
0.09
4.7
5.0
30.70
30.34
%
—
10
112
6
72
0.83
0.08
1.3
1.4
—
—
—
0
0
145
1462
0.95
0.05
5.2
5.1
1.41
1.41
mmol/l
0.04
135
1354
150
1490
1.05
0.03
5.9
5.8
2.54
2.74
mmol/l
1.93
141
1384
37
360
1.04
0.03
6.6
3.6
1.01
1.02
kg/l
2.10
23
247
18
172
1.05
0.02
2.5
2.4
9.82
14.08
nmol/l
1.65
18
161
12
116
1.04
0.00
1.2
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
-0.00
0.0
3.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.3
—
64.00
—
0
6
0
7
0.00
-0.00
0.0
2.9
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
0.16
—
0
7
0
6
0.00
-0.00
0.0
1.0
—
43.82
—
0
6
0
6
0.00
-0.00
0.0
3.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.9
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
6.92
—
0
5
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: ST19_INJURY_BLOOD_VESSE_LOWER_LEG_LEVEL – Injury of blood vessels at lower leg level
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).